Henry Schein Inc 10-Q for FY2021 Q1
Henry Schein Inc (HSIC)
10-Q
2021-05-04
For: 2021-03-27
View Original
Added on
April 04, 2026
About this 10-Q
Henry Schein Inc filed this 10-Q on May 4, 2021, covering the quarter ended March 27, 2021 (FY2021 Q1).
Headline figures
Quarter ended March 27, 2021, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $2.92B
- up 20.4% from $2.43B a year earlier
- Net income
- $166M
- up 27.4% from net income of $130.26M a year earlier
- Diluted EPS
- $1.16
- up 27.5% from $0.91 a year earlier
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934
For the
quarterly
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934
For the transition period from ____________ to ____________
Commission File Number:
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of
(I.R.S. Employer Identification No.)
incorporation or organization)
,
(Address of principal executive offices)
(Zip Code)
(
)
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
The Nasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past 90 days.
☒
No
☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted
pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was
required to submit such files).
☒
No
☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller
reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
☒
Accelerated filer
☐
Non-accelerated filer
☐
Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes
☐
No
☒
As of April 26, 2021,
there were
HENRY SCHEIN, INC.
INDEX
Page
3
4
5
6
7
8
8
9
10
11
12
15
17
17
19
21
22
23
24
25
26
28
28
31
32
46
47
48
48
48
49
50
See accompanying notes.
3
PART I. FINANCIAL INFORMATION
ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS
HENRY SCHEIN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
March 27,
December 26,
2021
2020
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents
$
$
Accounts receivable, net of reserves of $
Inventories, net
Prepaid expenses and other
Total current assets
Property and equipment, net
Operating lease right-of-use assets
Goodwill
Other intangibles, net
Investments and other
Total assets
$
$
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
$
$
Bank credit lines
Current maturities of long-term debt
111,176
109,836
Operating lease liabilities
Accrued expenses:
Payroll and related
Taxes
Other
Total current liabilities
Long-term debt
506,461
515,773
Deferred income taxes
Operating lease liabilities
Other liabilities
Total liabilities
Redeemable noncontrolling interests
Commitments and contingencies
Stockholders' equity:
Preferred stock, $
Common stock, $
Additional paid-in capital
Retained earnings
Accumulated other comprehensive loss
(136,305 )
(108,084 )
Total Henry Schein, Inc. stockholders' equity
Noncontrolling interests
Total stockholders' equity
Total liabilities, redeemable noncontrolling interests and stockholders' equity
$
$
See accompanying notes.
4
HENRY SCHEIN, INC.
CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share data)
(unaudited)
Three Months Ended
March 27,
March 28,
2021
2020
Net sales
$
$
Cost of sales
Gross profit
Operating expenses:
Selling, general and administrative
Restructuring costs
Operating income
Other income (expense):
Interest income
Interest expense
(6,485 )
(7,812 )
Other, net
(220 )
Income from continuing operations before taxes, equity in
earnings of affiliates and noncontrolling interests
Income taxes
(56,685 )
(37,910 )
Equity in earnings of affiliates
Net income from continuing operations
Loss from discontinued operations
(282 )
Net Income
Less: Net income attributable to noncontrolling interests
(8,931 )
(3,304 )
Net income attributable to Henry Schein, Inc.
$
$
Amounts attributable to Henry Schein, Inc.:
Continuing operations
$
$
Discontinued operations
(282 )
Net income attributable to Henry Schein, Inc.
$
$
Earnings per share from continuing operations attributable to Henry Schein, Inc.:
Basic
$
$
Diluted
$
$
Loss per share from discontinued operations attributable to Henry Schein, Inc.:
Basic
$
$
Diluted
$
$
Earnings per share attributable to Henry Schein, Inc.:
Basic
$
$
Diluted
$
$
Weighted -average common shares outstanding:
Basic
Diluted
See accompanying notes.
5
HENRY SCHEIN, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(in thousands)
(unaudited)
Three Months Ended
March 27,
March 28,
2021
2020
Net income
$
$
Other comprehensive loss, net of tax:
Foreign currency translation loss
(38,481 )
(89,312 )
Unrealized gain from foreign currency hedging activities
Unrealized investment loss
(6 )
(9 )
Pension adjustment gain
Other comprehensive loss, net of tax
(34,319 )
(73,454 )
Comprehensive income
Comprehensive (income) loss attributable to noncontrolling interests:
Net income
(8,931 )
(3,304 )
Foreign currency translation loss
Comprehensive (income) loss attributable to noncontrolling interests
(2,833 )
Comprehensive income attributable to Henry Schein, Inc.
$
$
See accompanying notes.
6
HENRY SCHEIN, INC.
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY
(in thousands, except share and per share data)
(unaudited)
Accumulated
Common Stock
Additional
Other
Total
$.01 Par Value
Paid-in
Retained
Comprehensive
Noncontrolling
Stockholders'
Shares
Amount
Capital
Earnings
Income / (Loss)
Equity
Balance, December 26, 2020
$
$
$
$
(108,084 )
$
$
Net income (excluding $
noncontrolling interests from continuing operations)
-
Foreign currency translation loss (excluding loss of $
attributable to Redeemable noncontrolling interests)
-
(32,383 )
(32,308 )
Unrealized gain from foreign currency hedging activities,
net of tax of $
-
Unrealized investment loss, net of tax benefit of $
-
(6 )
(6 )
Pension adjustment gain, net of tax of $
-
Dividends paid
-
(77 )
(77 )
Change in fair value of redeemable securities
-
(45,520 )
(45,520 )
Initial noncontrolling interests and adjustments related to
business acquisitions
-
Repurchase and retirement of common stock
(1,325,242 )
(13 )
(12,250 )
(76,396 )
(88,659 )
Stock-based compensation expense
Settlement of stock-based compensation awards
-
Shares withheld for payroll taxes
(108,861 )
(2 )
(7,176 )
(7,178 )
Transfer of charges in excess of capital
-
(51,372 )
Balance, March 27, 2021
$
$
$
$
(136,305 )
$
$
Accumulated
Common Stock
Additional
Other
Total
$.01 Par Value
Paid-in
Retained
Comprehensive
Noncontrolling
Stockholders'
Shares
Amount
Capital
Earnings
Income / (Loss)
Equity
Balance, December 28, 2019
$
$
$
$
(167,373 )
$
$
Cumulative impact of adopting new accounting standards
-
(412 )
(412 )
Net income (excluding $
noncontrolling interests from continuing operations)
-
Foreign currency translation loss (excluding loss of $
attributable to Redeemable noncontrolling interests)
-
(76,133 )
(152 )
(76,285 )
Unrealized gain from foreign currency hedging activities,
net of tax of $
-
Unrealized investment loss, net of tax benefit of $
-
(9 )
(9 )
Pension adjustment gain, net of tax of $
-
Dividends paid
-
(499 )
(499 )
Purchase of noncontrolling interests
-
(1,597 )
(692 )
(2,289 )
Change in fair value of redeemable securities
-
Repurchase and retirement of common stock
(1,200,000 )
(12 )
(10,949 )
(62,828 )
(73,789 )
Stock-based compensation credit
(17,519 )
(17,514 )
Shares withheld for payroll taxes
(227,509 )
(3 )
(13,871 )
(13,874 )
Settlement of stock-based compensation awards
-
Separation of Animal Health business
-
Balance, March 28, 2020
$
$
$
$
(227,648 )
$
$
See accompanying notes.
7
HENRY SCHEIN, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
Three Months Ended
March 27,
March 28,
2021
2020
Cash flows from operating activities:
Net income
$
$
Loss from discontinued operations
(282 )
Income from continuing operations
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
Impairment charge on intangible assets
Stock-based compensation (credit) expense
(17,514 )
Provision for (benefit from) losses on trade and other accounts receivable
(2,696 )
Provision for deferred income taxes
Equity in earnings of affiliates
(5,878 )
(2,734 )
Distributions from equity affiliates
Changes in unrecognized tax benefits
(1,575 )
Other
(13,924 )
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable
(1,283 )
Inventories
(78,085 )
Other current assets
(45,310 )
(22,002 )
Accounts payable and accrued expenses
(179,725 )
(137,680 )
Net cash provided by operating activities from continuing operations
Net cash used in operating activities from discontinued operations
(282 )
Net cash provided by operating activities
Cash flows from investing activities:
Purchases of fixed assets
(13,843 )
(23,008 )
Payments related to equity investments and business
acquisitions, net of cash acquired
(204,027 )
(37,947 )
Proceeds from sale of equity investment
Repayments from loan to affiliate
Other
(5,513 )
(5,787 )
Net cash used in investing activities from continuing operations
(223,244 )
(53,605 )
Net cash used in investing activities from discontinued operations
Net cash used in investing activities
(223,244 )
(53,605 )
Cash flows from financing activities:
Net change in bank borrowings
(241 )
Proceeds from issuance of long-term debt
Principal payments for long-term debt
(17,781 )
(8,478 )
Debt issuance costs
(85 )
(58 )
Payments for repurchases of common stock
(88,659 )
(73,789 )
Payments for taxes related to shares withheld for employee taxes
(6,158 )
(13,155 )
Distributions to noncontrolling shareholders
(6,520 )
(3,664 )
Acquisitions of noncontrolling interests in subsidiaries
(14,925 )
Payments to Henry Schein Animal Health Business
(2,962 )
Net cash provided by (used in) financing activities from continuing operations
(119,444 )
Net cash provided by financing activities from discontinued operations
Net cash provided by (used in) financing activities
(119,444 )
Effect of exchange rate changes on cash and cash equivalents from continuing operations
(5,489 )
Effect of exchange rate changes on cash and cash equivalents from discontinued operations
Net change in cash and cash equivalents from continuing operations
(276,647 )
Net change in cash and cash equivalents from discontinued operations
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
$
$
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
)
8
Note 1
Basis of Presentation
Our consolidated financial statements include our accounts, as well as those of our wholly-owned and majority-
owned subsidiaries. Certain prior period amounts have been reclassified to conform to the current period
presentation.
Our accompanying unaudited consolidated financial statements have been prepared in accordance with accounting
principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the
instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the
information and footnote disclosures required by U.S. GAAP for complete financial statements.
have the power to direct activities that most significantly affect the economic performance and have the obligation
to absorb the majority of the losses or benefits. The results of operations and financial position of this VIE are
included in our consolidated financial statements.
For the consolidated VIE, the trade accounts receivable transferred to the VIE are pledged as collateral to the
related debt.
and December 26, 2020,
The consolidated financial statements reflect all adjustments considered necessary for a fair presentation of the
consolidated results of operations and financial position for the interim periods presented. All such adjustments are
of a normal recurring nature. These unaudited interim consolidated financial statements should be read in
conjunction with the audited consolidated financial statements and notes to the consolidated financial statements
contained in our Annual Report on Form 10-K for the year ended December 26, 2020.
The preparation of financial statements in conformity with accounting principles generally accepted in the United
States
disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of
revenues and expenses during the reporting period. Actual results could differ from those estimates. The results of
operations for the three months ended March 27, 2021 are not necessarily indicative of the results to be expected
for any other interim period or for the year ending December 25, 2021.
In March 2020, the World Health Organization declared the Novel Coronavirus Disease 2019 (“COVID-19”) a
pandemic. The COVID-19 pandemic negatively impacted the global economy, disrupted global supply chains and
created significant volatility and disruption of global financial markets. In response, many countries implemented
business closures and restrictions, stay-at-home and social distancing ordinances and similar measures to combat
the pandemic, which significantly impacted global business and dramatically reduced demand for dental products
and certain medical products in the second quarter of 2020.
Demand increased in the second half of 2020 and has
continued into the first quarter of 2021, resulting in growth over the prior year driven by sales of personal
protective equipment (PPE) and COVID-19 related products.
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
)
9
Our consolidated financial statements reflect estimates and assumptions made by us that affect, among other things,
our goodwill, long-lived asset and definite-lived intangible asset valuation; inventory valuation; equity investment
valuation; assessment of the annual effective tax rate; valuation of deferred income taxes and income tax
contingencies; the allowance for doubtful accounts; hedging activity; vendor rebates; measurement of
compensation cost for certain share-based performance awards and cash bonus plans; and pension plan
assumptions. Due to the significant uncertainty surrounding the future impact of COVID-19, our judgments
regarding estimates and impairments could change in the future. In addition, the impact of COVID-19 had a
material adverse effect on our business, results of operations and cash flows, primarily in the second quarter of
2020. In the latter half of the second quarter of 2020, dental and medical practices began to re-open worldwide, and
continued to do so during the second half of 2020. During the first quarter of 2021, patient traffic levels returned to
levels approaching pre-pandemic levels, although certain regions in the U.S. and internationally are experiencing an
increase in COVID-19 cases. There is an ongoing risk that the COVID-19 pandemic may again have a material
adverse effect on our business, results of operations and cash flows and may result in a material adverse effect on
our financial condition and liquidity. However, the extent of the potential impact cannot be reasonably estimated at
this time.
Note 2 – Critical Accounting Policies, Accounting Pronouncements Adopted and Recently Issued Accounting
Standards
Critical Accounting Policies
There have been no material changes in our critical accounting policies during the three months ended March 27,
2021, as compared to the critical accounting policies described in Item 8 to the consolidated financial statements
included in our Annual Report on Form 10-K for the year ended December 26, 2020, except as follows:
Accounting Pronouncements Adopted
In
December 2019
, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update
(“ASU”) No. 2019-12, “Income Taxes” (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-
12”). ASU 2019-12 will simplify the accounting for income taxes by removing certain exceptions to the general
principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other
areas of Topic 740 by clarifying and amending existing guidance. Our
material impact on our consolidated financial statements.
Recently Issued Accounting Standards
In August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options” (Subtopic
470-20) and “Derivatives and Hedging— in Entity’s Own Equity” (Subtopic 815-40): Accounting for Convertible
Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). ASU 2020-06 simplifies the accounting
for convertible instruments. In addition to eliminating certain accounting models, this ASU includes improvements
to the disclosures for convertible instruments and earnings-per-share (EPS) guidance and amends the guidance for
the derivatives scope exception for contracts in an entity’s own equity. ASU 2020-06 is effective for fiscal years
beginning after December 15, 2021. We do not expect that the requirements of this ASU will have a material
impact on our consolidated financial statements.
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
)
10
Note 3 – Revenue from Contracts with Customers
Revenue is recognized in accordance with policies disclosed in Item 8 of our Annual Report on Form 10-K for
the year ended December 26, 2020.
Disaggregation of Revenue
The following table disaggregates our revenue by segment and geography:
Three Months Ended
March 27, 2021
North America
International
Global
Revenues:
Health care distribution
Dental
$
Medical
Total health care distribution
Technology and value-added services
Total revenues
$
$
$
Three Months Ended
March 28, 2020
North America
International
Global
Revenues:
Health care distribution
Dental
$
Medical
Total health care distribution
Technology and value-added services
Total excluding Corporate TSA revenues
Corporate TSA revenues
Total revenues
$
$
$
(1)
Corporate TSA revenues represents sales of certain animal health products to Covetrus under the transition services agreement
entered into in connection with the Animal Health Spin-off, which ended in December 2020. See
At December 26, 2020, the current portion of contract liabilities of $
expenses: Other, and $
During the three months ended March 27, 2021, we recognized in revenue $
previously deferred at December 26, 2020. At March 27, 2021, the current and non-current portion of contract
liabilities were $
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
)
11
Note 4
Segment Data
We conduct our business through
value-added services. These segments offer different products and services to the same customer base.
The health care distribution reportable segment aggregates our global dental and medical operating segments. This
segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair
services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control
products and vitamins. Our global dental group serves office-based dental practitioners, dental laboratories, schools
and other institutions. Our global medical group serves office-based medical practitioners, ambulatory surgery
centers, other alternate-care settings and other institutions. Our global dental and medical groups serve
practitioners in
Our global technology and value-added services group provides software, technology and other value-added
services to health care practitioners. Our technology group offerings include practice management software
systems for dental and medical practitioners. Our value-added practice solutions include financial services on a
non-recourse basis, e-services, practice technology, network and hardware services, as well as continuing education
services for practitioners.
The following tables present information about our reportable and operating segments:
Three Months Ended
March 27,
March 28,
2021
2020
Net Sales:
Health care distribution
(1)
Dental
$
$
Medical
Total health care distribution
Technology and value-added services
(2)
Total excluding Corporate TSA revenue
Corporate TSA revenues
(3)
Total
$
$
(1)
Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and
generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, personal protective equipment
and vitamins.
(2)
Consists of practice management software and other value-added products, which are distributed primarily to health care providers,
and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other
services.
(3)
Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered into in
connection with the Animal Health Spin-off, which ended in December 2020. See
information.
Three Months Ended
March 27,
March 28,
2020
2020
Operating Income:
Health care distribution
$
197,932
$
148,167
Technology and value-added services
31,996
25,698
Total
$
229,928
$
173,865
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
)
12
Note 5 – Debt
Bank Credit Lines
Bank credit lines consisted of the following:
March 27,
December 26,
2021
2020
Revolving credit agreement
$
$
Other short-term bank credit lines
Total
$
$
Revolving Credit Agreement
On
, we entered into a $
matures in
April 2022
. The interest rate is based on the USD LIBOR plus a spread based on our leverage ratio at
the end of each financial reporting quarter. We expect most LIBOR rates to be discontinued immediately after
December 31, 2021, while the remaining LIBOR rates will be discontinued immediately after June 30, 2023, which
will require an amendment to our debt agreements to reflect a new reference rate. We do not expect the
discontinuation of LIBOR as a reference rate in our debt agreements to have a material adverse effect on our
financial position or to materially affect our interest expense. The Credit Agreement also requires, among other
things, that we maintain maximum leverage ratios. Additionally, the Credit Agreement contains customary
representations, warranties and affirmative covenants as well as customary negative covenants, subject to
negotiated exceptions on liens, indebtedness, significant corporate changes (including mergers), dispositions and
certain restrictive agreements. As of March 27, 2021, and December 26, 2020, we had no borrowings on this
revolving credit facility. As of March 27, 2021, and December 26, 2020, there were $
of letters of credit, respectively, provided to third parties under the credit facility.
On April 17, 2020, we amended the Credit Agreement to, among other things, (i) modify the financial covenant
from being based on total leverage ratio to net leverage ratio, (ii) adjust the pricing grid to reflect the net leverage
ratio calculation, and (iii) increase the maximum maintenance leverage ratio through March 31, 2021.
364-Day Credit Agreement
On March 4, 2021 we repaid the outstanding obligations and terminated the lender commitments under our $
million
-day credit agreement which was entered into on
. This facility was originally scheduled
to mature on
.
Other Short-Term Credit Lines
As of March 27, 2021 and December 26, 2020, we had various other short-term bank credit lines available, of
which $
2020, borrowings under all of these credit lines had a weighted average interest rate of
% and
%,
respectively.
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
)
13
Long-term debt
Long-term debt consisted of the following:
March 27,
December 26,
2021
2020
Private placement facilities
$
$
Note payable
Various collateralized and uncollateralized loans payable with interest,
in varying installments through
ranging from
% to
% at March 27, 2021 and
ranging from
% to
% at December 26, 2020
Finance lease obligations (see Note 7)
Total
Less current maturities
(111,176 )
(109,836 )
Total long-term debt
$
$
Private Placement Facilities
Our private placement facilities, with
available on an uncommitted basis at fixed rate economic terms to be agreed upon at the time of issuance, from
time to time through
. The facilities allow us to issue senior promissory notes to the lenders at a fixed
rate based on an agreed upon spread over applicable treasury notes at the time of issuance. The term of each
possible issuance will be selected by us and can range from
five
years). The proceeds of any issuances under the facilities will be used for general corporate purposes, including
working capital and capital expenditures, to refinance existing indebtedness and/or to fund potential acquisitions.
The agreements provide, among other things, that we maintain certain maximum leverage ratios, and contain
restrictions relating to subsidiary indebtedness, liens, affiliate transactions, disposal of assets and certain changes in
ownership. These facilities contain make-whole provisions in the event that we pay off the facilities prior to the
applicable due dates.
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
)
14
The components of our private placement facility borrowings as of March 27, 2021 are presented in the following
table (in thousands):
Amount of
Borrowing
Borrowing
Date of Borrowing
Outstanding
Rate
Due Date
January 20, 2012
$
%
January 20, 2022
January 20, 2012
January 20, 2024
December 24, 2012
December 24, 2024
June 2, 2014
June 2, 2021
June 16, 2017
June 16, 2027
September 15, 2017
September 15, 2029
January 2, 2018
January 2, 2028
September 2, 2020
September 2, 2030
Less: Deferred debt issuance costs
(788 )
$
(1)
.
U.S. Trade Accounts Receivable Securitization
We have a facility agreement with a bank, as agent, based on the securitization of our U.S. trade accounts
receivable that is structured as an asset-backed securitization program with pricing committed for up to
.
Our current facility, which has a purchase limit of $
. On
June 22, 2020, the expiration date for this facility was extended to
covenant levels for 2020. As of March 27, 2021 and December 26, 2020, there were
under this securitization facility. At March 27, 2021, the interest rate on borrowings under this facility was based
on the asset-backed commercial paper rate of
% plus
%, for a combined rate of
%. At December 26,
2020, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of
% plus
%, for a combined rate of
%.
If our accounts receivable collection pattern changes due to customers either paying late or not making payments,
our ability to borrow under this facility may be reduced.
We are required to pay a commitment fee of
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
)
15
Note 6 – Leases
Leases
, some of
which
. The components of lease expense were as
follows:
Three Months Ended
March 27,
March 28,
2021
2020
Operating lease cost:
(1)
$
$
Finance lease cost:
Amortization of right-of-use assets
Interest on lease liabilities
Total finance lease cost
$
$
(1)
Includes variable lease expenses.
Supplemental balance sheet information related to leases is as follows:
March 27,
December 26,
2021
2020
Operating Leases:
Operating lease right-of-use assets
$
$
Current operating lease liabilities
Non-current operating lease liabilities
Total operating lease liabilities
$
$
Finance Leases:
Property and equipment, at cost
$
$
Accumulated depreciation
(4,607 )
(4,277 )
Property and equipment, net of accumulated depreciation
$
$
Current maturities of long-term debt
$
$
Long-term debt
Total finance lease liabilities
$
$
Weighted Average Remaining Lease Term in Years:
Operating leases
Finance leases
Weighted Average Discount Rate:
Operating leases
%
%
Finance leases
%
%
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
)
16
Supplemental cash flow information related to leases is as follows:
Three Months Ended
March 27,
March 28,
2021
2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases
$
$
Operating cash flows for finance leases
Financing cash flows for finance leases
Right-of-use assets obtained in exchange for lease obligations:
Operating leases
$
$
Finance leases
Maturities of lease liabilities are as follows:
March 27, 2021
Operating
Finance
Leases
Leases
2021
$
$
2022
2023
2024
2025
Thereafter
Total future lease payments
Less: imputed interest
(31,796 )
(202 )
Total
$
$
As of March 27, 2021, we have additional operating leases with total lease payments of $
with lease terms of
.
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
)
17
Note 7 – Redeemable Noncontrolling Interests
Some minority stockholders in certain of our subsidiaries have the right, at certain times, to require us to acquire
their ownership interest in those entities at fair value. Accounting Standards Codification (“ASC”) Topic 480-10 is
applicable for noncontrolling interests where we are or may be required to purchase all or a portion of the
outstanding interest in a consolidated subsidiary from the noncontrolling interest holder under the terms of a put
option contained in contractual agreements. The components of the change in the redeemable noncontrolling
interests for the three months ended March 27, 2021 and the year ended December 26, 2020 are presented in the
following table:
March 27,
December 26,
2021
2020
Balance, beginning of period
$
$
Decrease in redeemable noncontrolling interests due to
redemptions
(17,241 )
Increase in redeemable noncontrolling interests due to business
acquisitions
Net income attributable to redeemable noncontrolling interests
Dividends declared
(6,237 )
(12,631 )
Effect of foreign currency translation loss attributable to
redeemable noncontrolling interests
(6,173 )
(4,279 )
Change in fair value of redeemable securities
Balance, end of period
$
$
Note 8 – Comprehensive Income
Comprehensive income includes certain gains and losses that, under U.S. GAAP, are excluded from net income as
such amounts are recorded directly as an adjustment to stockholders’ equity.
The following table summarizes our Accumulated other comprehensive loss, net of applicable taxes as of:
March 27,
December 26,
2021
2020
Attributable to Redeemable noncontrolling interests:
Foreign currency translation adjustment
$
(30,790 )
$
(24,617 )
Attributable to noncontrolling interests:
Foreign currency translation adjustment
$
$
Attributable to Henry Schein, Inc.:
Foreign currency translation adjustment
$
(108,948 )
$
(76,565 )
Unrealized loss from foreign currency hedging activities
(8,127 )
(11,488 )
Unrealized investment gain (loss)
(5 )
Pension adjustment loss
(19,225 )
(20,032 )
Accumulated other comprehensive loss
$
(136,305 )
$
(108,084 )
Total Accumulated other comprehensive loss
$
(166,785 )
$
(132,466 )
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
)
18
The following table summarizes the components of comprehensive income, net of applicable taxes as follows:
Three Months Ended
March 27,
March 28,
2021
2020
Net income
$
$
Foreign currency translation loss
(38,481 )
(89,312 )
Tax effect
Foreign currency translation loss
(38,481 )
(89,312 )
Unrealized gain from foreign currency hedging activities
Tax effect
(1,334 )
(5,090 )
Unrealized gain from foreign currency hedging activities
Unrealized investment loss
(8 )
(11 )
Tax effect
Unrealized investment loss
(6 )
(9 )
Pension adjustment gain
Tax effect
(219 )
(324 )
Pension adjustment gain
Comprehensive income
$
$
Our financial statements are denominated in the U.S. Dollar currency. Fluctuations in the value of foreign
currencies as compared to the U.S. Dollar may have a significant impact on our comprehensive income. The
foreign currency translation loss during the three months ended March 27, 2021 and three months ended March 28,
2020 was primarily impacted by changes in foreign currency exchange rates of the Euro, British Pound, Brazilian
Real, Australian Dollar, and Canadian Dollar.
The following table summarizes our total comprehensive income, net of applicable taxes, as follows:
Three Months Ended
March 27,
March 28,
2021
2020
Comprehensive income attributable to
Henry Schein, Inc.
$
$
Comprehensive income attributable to
noncontrolling interests
Comprehensive income (loss) attributable to
Redeemable noncontrolling interests
(10,188 )
Comprehensive income
$
$
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
)
19
Note 9 – Fair Value Measurements
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date. Fair value hierarchy distinguishes between
(1) market participant assumptions developed based on market data obtained from independent sources (observable
inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best
information available in the circumstances (unobservable inputs).
The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices
in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).
The three levels of the fair value hierarchy are described as follows:
• Level 1— Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the
measurement date.
• Level 2— Inputs other than quoted prices included within Level 1 that are observable for the asset or liability,
either directly or indirectly. Level 2 inputs include: quoted prices for similar assets or liabilities in active markets;
quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted
prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by
observable market data by correlation or other means.
• Level 3— Inputs that are unobservable for the asset or liability.
The following section describes the fair values of our financial instruments and the methodologies that we used to
measure their fair values.
Investments and notes receivable
There are no quoted market prices available for investments in unconsolidated affiliates and notes receivable;
however, we believe the carrying amounts are a reasonable estimate of fair value based on the interest rates in the
applicable markets.
Debt
The fair value of our debt (including bank credit lines) is classified as Level 3 within the fair value hierarchy as of
March 27, 2021 and December 26, 2020 was estimated at $
that we considered when estimating the fair value of our debt include market conditions, such as interest rates and
credit spreads.
Derivative contracts
Derivative contracts are valued using quoted market prices and significant other observable and unobservable
inputs. We use derivative instruments to minimize our exposure to fluctuations in foreign currency exchange
rates. Our derivative instruments primarily include foreign currency forward agreements related to certain
intercompany loans, certain forecasted inventory purchase commitments with foreign suppliers, foreign currency
forward contracts to hedge a portion of our euro-denominated foreign operations which are designated as net
investment hedges and a total return swap for the purpose of economically hedging our unfunded non-qualified
supplemental retirement plan and our deferred compensation plan.
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
)
20
The fair values for the majority of our foreign currency derivative contracts are obtained by comparing our contract
rate to a published forward price of the underlying market rates, which is based on market rates for comparable
transactions and are classified within Level 2 of the fair value hierarchy. See
Redeemable noncontrolling interests
The values for Redeemable noncontrolling interests are classified within Level 3 of the fair value hierarchy and are
based on recent transactions and/or implied multiples of earnings. See
The following table presents our assets and liabilities that are measured and recognized at fair value on a recurring
basis classified under the appropriate level of the fair value hierarchy as of March 27, 2021 and December 26,
2020:
March 27, 2021
Level 1
Level 2
Level 3
Total
Assets:
Derivative contracts
$
$
$
$
Total return swaps
Total assets
$
$
$
$
Liabilities:
Derivative contracts
$
$
$
$
Total liabilities
$
$
$
$
Redeemable noncontrolling interests
$
$
$
$
December 26, 2020
Level 1
Level 2
Level 3
Total
Assets:
Derivative contracts
$
$
$
$
Total return swaps
Total assets
$
$
$
$
Liabilities:
Derivative contracts
$
$
$
$
Total liabilities
$
$
$
$
Redeemable noncontrolling interests
$
$
$
$
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
)
21
Note 10
Business Acquisitions
Acquisitions
We completed acquisitions during the three months ended March 27, 2021 which were immaterial to our financial
statements. The acquisitions that we completed included companies within our Health care distribution and
Technology and value-added services segments. Our initial ownership interest acquired ranges between
approximately
% to
%.
marketing and website solutions, practice transition services, and business analytics and intelligence software.
The following table summarizes the estimated fair value, as of the date of acquisition, of consideration paid and net
assets acquired for acquisitions during the three months ended March 27, 2021. While we use our best estimates
and assumptions to accurately value those assets acquired and liabilities assumed at the acquisition date as well as
contingent consideration, where applicable, our estimates are inherently uncertain and subject to refinement. As a
result, during the measurement period we may record adjustments to the assets acquired and liabilities assumed
with the corresponding offset to goodwill within our consolidated balance sheets.
Acquisition consideration:
Cash
$
Redeemable noncontrolling interests
Total consideration
Identifiable assets acquired and liabilities assumed:
Current assets
Intangible assets
Other noncurrent assets
Current liabilities
(31.8 )
Deferred income taxes
(9.4 )
Other noncurrent liabilities
(22.4 )
Total identifiable net assets
Goodwill
Total net assets acquired
$
The major classes of assets and liabilities that we generally allocate purchase price to, excluding goodwill, include
identifiable intangible assets (i.e., trademarks and trade names, customer relationships and lists, non-compete
agreements and product development), property, plant and equipment, deferred taxes and other current and long-
term assets and liabilities. The estimated fair value of identifiable intangible assets is based on critical estimates,
judgments and assumptions derived from analysis of market conditions, discount rates, discounted cash flows,
customer retention rates and estimated useful lives.
Some prior owners of acquired subsidiaries are eligible to receive additional purchase price cash consideration if
certain financial targets are met. We have accrued liabilities for the estimated fair value of additional purchase
price consideration at the time of the acquisition. Any adjustments to these accrual amounts are recorded in our
consolidated statements of income. For the three months ended March 27, 2021 and March 28, 2020, there were no
material adjustments recorded in our consolidated statements of income relating to changes in estimated contingent
purchase price liabilities.
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
)
22
Note 11 – Plans of Restructuring
On November 20, 2019, we committed to a contemplated initiative, intended to mitigate stranded costs associated
with the Animal Health Spin-off and to rationalize operations and to provide expense efficiencies. These activities
were originally expected to be completed by the end of 2020. In light of the changes to the business environment
brought on by the COVID-19 pandemic, we extended such activities to the end of 2021.
During the three months ended March 27, 2021 and March 28, 2020, we recorded restructuring costs of $
million and $
benefits and facility exit costs. The costs associated with these restructurings are included in a separate line item,
“Restructuring costs” within our consolidated statements of income.
We are currently unable in good faith to make a determination of an estimate of the amount or range of
amounts expected to be incurred in connection with these activities in 2021, both with respect to each major type of
cost associated therewith and with respect to the total cost, or an estimate of the amount or range of amounts that
will result in future cash expenditures.
The following table shows the net amounts expensed and paid for restructuring costs that were incurred during the
three months ended March 27, 2021 and during our 2020 fiscal year and the remaining accrued balance of
restructuring costs as of March 27, 2021, which is included in Accrued expenses: Other within our consolidated
balance sheets:
Facility
Severance
Closing
Costs
Costs
Other
Total
Balance, December 28, 2019
$
$
$
$
Provision
Payments and other adjustments
(26,152 )
(6,309 )
(329 )
(32,790 )
Balance, December 26, 2020
$
$
$
$
Provision
(151 )
Payments and other adjustments
(8,623 )
(243 )
(8,710 )
Balance, March 27, 2021
$
$
$
$
The following table shows, by reportable segment, the net amounts expensed and paid for restructuring costs that
were incurred during the three months ended March 27, 2021 and during our 2020 fiscal year and the remaining
accrued balance of restructuring costs as of March 27, 2021:
Technology and
Health Care
Value-Added
Distribution
Services
Total
Balance, December 28, 2019
$
$
$
Provision
Payments and other adjustments
(31,484 )
(1,306 )
(32,790 )
Balance, December 26, 2020
$
$
$
Provision
Payments and other adjustments
(8,531 )
(179 )
(8,710 )
Balance, March 27, 2021
$
$
$
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
)
23
Note 12
Earnings Per Share
Basic earnings per share is computed by dividing net income attributable to Henry Schein, Inc. by the weighted-
average number of common shares outstanding for the period. Our diluted earnings per share is computed similarly
to basic earnings per share, except that it reflects the effect of common shares issuable for presently unvested
restricted stock and restricted stock units and upon exercise of stock options using the treasury stock method in
periods in which they have a dilutive effect.
A reconciliation of shares used in calculating earnings per basic and diluted share follows:
Three Months Ended
March 27,
March 28,
2021
2020
Basic
Effect of dilutive securities:
Stock options, restricted stock and restricted stock units
Diluted
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
)
24
Note 13 – Income Taxes
For the three months ended March 27, 2021 our effective tax rate was
% compared to
% for the prior year
period. The difference between our effective tax rate and the federal statutory tax rate for the three months ended
March 27, 2021 was primarily due to state and foreign income taxes and interest expense. The difference between
our effective tax rate and the federal statutory tax rate for the three months ended March 28, 2020 primarily relates
to state and foreign income taxes and interest expense as well as tax charges and credits associated with legal entity
reorganizations outside the United States.
The American Rescue Plan Act of 2021 (“ARPA”) was signed into law on March 11, 2021. The ARPA included a
corporate income tax provision to further limit the deductibility of compensation under Section 162(m) for tax
years starting after December 31, 2026. Section 162(m) generally limits the deductibility of compensation paid to
covered employees of publicly held corporations. Covered employees include the CEO, CFO and the three highest
paid officers. The ARPA expands the group of covered employees to additionally include five of the highest paid
employees.
On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted in
response to the COVID-19 pandemic. The CARES Act includes, but is not limited to, certain income tax
provisions that modify the Section 163(j) limitation of business interest and net operating loss carryover and
carryback rules. We have analyzed the income tax provisions of the CARES Act and have accounted for the
impact in the three months ended March 28, 2020, which did not have a material impact on our consolidated
financial statements. There are certain other non-income tax benefits available to us under the CARES Act that
require further clarification or interpretation that may affect our consolidated financial statements in the future.
The total amount of unrecognized tax benefits, which are included in “Other liabilities” within our consolidated
balance sheets, as of March 27, 2021 was approximately $
effective tax rate if recognized. It is possible that the amount of unrecognized tax benefits will change in the next
12 months, which may result in a material impact on our consolidated statements of income.
The total amounts of interest and penalties are classified as a component of the provision for income taxes. The
amount of tax interest expense was approximately $
$
liabilities”, and was approximately $
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
)
25
Note 14
Derivatives and Hedging Activities
We are exposed to market risks as well as changes in foreign currency exchange rates as measured against the U.S.
dollar and each other, and changes to the credit risk of the derivative counterparties. We attempt to minimize these
risks by primarily using foreign currency forward contracts and by maintaining counter-party credit limits. These
hedging activities provide only limited protection against currency exchange and credit risks. Factors that could
influence the effectiveness of our hedging programs include currency markets and availability of hedging
instruments and liquidity of the credit markets. All foreign currency forward contracts that we enter into are
components of hedging programs and are entered into for the sole purpose of hedging an existing or anticipated
currency exposure. We do not enter into such contracts for speculative purposes and we manage our credit risks by
diversifying our counterparties, maintaining a strong balance sheet and having multiple sources of capital.
During 2019
effectiveness are included in interest expense within our consolidated statements of income. The aggregate
notional value of this net investment hedge, which matures on
, is approximately €
During the three months ended March 27, 2021 and March 28, 2020, we recognized approximately $
million, respectively, of interest savings as a result of this net investment hedge.
On
,
plans was $
million. At March 27, 2021, the financing blended rate for this swap was based on LIBOR of
% plus
%,
for a combined rate of
%. For the three months ended March 27, 2021, we have recorded a gain, within the
selling, general and administrative line item in our consolidated statement of income, of approximately $
million, net of transaction costs, related to this undesignated swap. This swap is expected to be renewed on an
annual basis after its current expiration date of March 29, 2022, and is expected to result in a neutral impact to our
results of operations.
Fluctuations in the value of certain foreign currencies as compared to the U.S. dollar may positively or negatively
affect our revenues, gross margins, operating expenses and retained earnings, all of which are expressed in U.S.
dollars. Where we deem it prudent, we engage in hedging programs using primarily foreign currency forward
contracts aimed at limiting the impact of foreign currency exchange rate fluctuations on earnings. We purchase
short-term (i.e., generally
exchange risks associated with intercompany loans due from our international subsidiaries and the payment of
merchandise purchases to our foreign suppliers. We do not hedge the translation of foreign currency profits into
U.S. dollars, as we regard this as an accounting exposure, not an economic exposure. Our hedging activities have
historically not had a material impact on our consolidated financial statements. Accordingly, additional disclosures
related to derivatives and hedging activities required by ASC 815 have been omitted.
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
)
26
Note 15 – Stock-Based Compensation
Our accompanying consolidated statements of income reflect pre-tax share-based compensation expense of $
million ($
credit of $
credit for share-based compensation during the three months ended March 28, 2020 reflected our reduced estimate
in expected achievement of performance targets resulting from the impact of COVID-19.
Our accompanying consolidated statements of cash flows present our stock-based compensation expense (credit) as
an adjustment to reconcile net income to net cash provided by operating activities for all periods presented. In the
accompanying consolidated statements of cash flows, there were
excess of recognized compensation as a cash inflow from financing activities for the three months ended March 27,
2021 and March 28, 2020, respectively.
Stock-based compensation represents the cost related to stock-based awards granted to employees and non-
employee directors. We measure stock-based compensation at the grant date, based on the estimated fair value of
the award, and recognize the cost (net of estimated forfeitures) as compensation expense over the requisite service
period. Our stock-based compensation expense is reflected in selling, general and administrative expenses in our
consolidated statements of income.
Stock-based awards are provided to certain employees and non-employee directors under the terms of our 2020
Stock Incentive Plan and our 2015 Non-Employee Director Stock Incentive Plan (together, the “Plans”). The Plans
are administered by the Compensation Committee of the Board of Directors (the “Compensation
Committee”). Historically, equity-based awards have been granted solely in the form of restricted stock units
(“RSUs”). However, in March 2021, our equity-based awards were granted in the form of RSUs and non-qualified
stock options.
Grants of RSUs are stock-based awards granted to recipients with specified vesting provisions. In the case of
RSUs, common stock is generally delivered on or following satisfaction of vesting conditions. We issue RSUs that
vest solely based on the recipient’s continued service over time (primarily four-year cliff vesting, except for grants
made under the 2015 Non-Employee Director Stock Incentive Plan, which are primarily
-month cliff vesting),
and RSUs that vest based on our achieving specified performance measurements and the recipient’s continued
service over time (primarily three-year cliff vesting). For these RSUs, we recognize the cost as compensation
expense on a straight-line basis.
During the three months ended March 27, 2021, as a result of the continuing economic risk and uncertainty
resulting from the ongoing COVID-19 pandemic, the Compensation Committee decided to adjust the form of
awards granted under our 2021 long-term incentive program for our 2021 fiscal year in a manner that focuses on
our long-term value by granting stock options and time-based RSUs rather than performance-based RSUs. Stock
options are awards that allow the recipient to purchase shares of our common stock at a fixed price following
vesting of the stock options. Stock options are granted at an exercise price equal to our closing stock price on the
date of grant. Stock options issued during 2021 vest
one-third
subject to the terms and conditions of the Plans, are fully vested
contractual term of
Compensation expense for these stock options is recognized using a graded vesting method. We estimate the fair
value of stock options using the Black-Scholes valuation model.
In addition to equity-based awards under the 2021 long-term incentive program under the 2020 Stock Incentive
Plan, the Compensation Committee granted a Special Pandemic Recognition Award under the 2020 Stock Incentive
Plan to recipients of performance-based RSUs under the 2018 long-term incentive program. These awards will vest
% on the first anniversary of the grant date and
% on the second anniversary of the grant date and are recorded
as compensation expense using a graded vesting method.
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
)
27
With respect to time-based RSUs, we estimate the fair value on the date of grant based on our closing stock price at
time of grant. With respect to performance-based RSUs, the number of shares that ultimately vest and are received
by the recipient is based upon our performance as measured against specified targets over a specified period, as
determined by the Compensation Committee. Although there is no guarantee that performance targets will be
achieved, we estimate the fair value of performance-based RSUs based on our closing stock price at time of grant.
The Plans provide for adjustments to the performance-based restricted stock units targets for significant events,
including, without limitation, acquisitions, divestitures, new business ventures, certain capital transactions
(including share repurchases), restructuring costs, if any, certain litigation settlements or payments, if any, changes
in accounting principles or in applicable laws or regulations, changes in income tax rates in certain markets and
foreign exchange fluctuations. Over the performance period, the number of shares of common stock that will
ultimately vest and be issued and the related compensation expense is adjusted upward or downward based upon
our estimation of achieving such performance targets. The ultimate number of shares delivered to recipients and
the related compensation cost recognized as an expense will be based on our actual performance metrics as defined
under the Plans.
Total unrecognized compensation cost related to unvested awards as of March 27, 2021 was $
is expected to be recognized over a weighted-average period of approximately
The following weighted-average assumptions were used in determining the fair values of stock options using the
Black-Scholes valuation model:
Expected dividend yield
%
Expected stock price volatility
%
Risk-free interest rate
%
Expected life of options (years)
We have not declared cash dividends on our stock in the past and we do not anticipate declaring cash dividends in
the foreseeable future. The expected stock price volatility is based on implied volatilities from traded options on our
stock, historical volatility of our stock, and other factors. The risk-free interest rate is based on the U.S. Treasury
yield curve in effect at the time of grant in conjunction with considering the expected life of options. The
-year
expected life of the options was determined using the simplified method for estimating the expected term as
permitted under SAB Topic 14. Estimates of fair value are not intended to predict actual future events or the value
ultimately realized by recipients of stock options, and subsequent events are not indicative of the reasonableness of
the original estimates of fair value made by us.
The following table summarizes stock option activity under the Plans during the three months ended March 27,
2021:
Weighted
Average
Weighted
Remaining
Average
Contractual
Aggregate
Exercise
Life in
Shares
Price
Years
Outstanding at beginning of period
$
Granted
Forfeited
Outstanding at end of period
$
$
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
)
28
The following tables summarize the activity of our unvested RSUs for the three months ended March 27, 2021:
Time-Based Restricted Stock Units
Weighted Average
Grant Date Fair
Intrinsic Value
Shares/Units
Value Per Share
Per Share
Outstanding at beginning of period
$
Granted
Vested
(256 )
Forfeited
(7 )
Outstanding at end of period
$
$
Performance-Based Restricted Stock Units
Weighted Average
Grant Date Fair
Intrinsic Value
Shares/Units
Value Per Share
Per Share
Outstanding at beginning of period
$
Granted
Vested
(78 )
Forfeited
(4 )
Outstanding at end of period
$
$
Note 16 – Supplemental Cash Flow Information
Cash paid for interest and income taxes was:
Three Months Ended
March 27,
March 28,
2021
2020
Interest
$
$
Income taxes
During the three months ended March 27, 2021 and March 28, 2020, we had a $
non-cash net unrealized gains related to foreign currency hedging activities, respectively.
Note 17 – Legal Proceedings
On
August 31, 2012
,
U.S. District Court for the Eastern District of Texas, Civil Action No. 2:12-CV-00572-JRG, styled as an antitrust
action under Section 1 of the Sherman Act, and the Texas Free Enterprise Antitrust Act.
August 1, 2017
,
, and
trial, to be trebled with interest and costs, including attorneys’ fees, jointly and severally, as well as injunctive
relief. On
October 30, 2017
,
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
)
29
On October 1, 2012, we filed a motion for an order: (i) compelling Archer to arbitrate its claims against us; (2)
staying all proceedings pending arbitration; and (3) joining the Danaher Defendants’ motion to arbitrate and stay.
On May 28, 2013, the Magistrate Judge granted the motions to arbitrate and stayed proceedings pending arbitration.
On June 10, 2013, Archer moved for reconsideration before the District Court judge. On December 7, 2016, the
District Court Judge granted Archer’s motion for reconsideration and lifted the stay. Defendants appealed the
District Court’s order. On December 21, 2017, the U.S. Court of Appeals for the Fifth Circuit affirmed the District
Court’s order denying the motions to compel arbitration. On June 25, 2018, the Supreme Court of the United States
granted defendants’ petition for writ of certiorari. On October 29, 2018, the Supreme Court heard oral arguments.
On January 8, 2019, the Supreme Court issued its published decision vacating the judgment of the Fifth Circuit and
remanding the case to the Fifth Circuit for further proceedings consistent with the Supreme Court’s opinion. On
April 2, 2019, the District Court stayed the proceeding in the trial court pending resolution by the Fifth Circuit. The
Fifth Circuit heard oral argument on May 1, 2019 on whether the case should be arbitrated. The Fifth Circuit
issued its opinion on August 14, 2019 affirming the District Court’s order denying defendants’ motions to compel
arbitration. Defendants filed a petition for rehearing en banc before the Fifth Circuit. The Fifth Circuit denied that
petition. On October 1, 2019, the District Court set the case for trial on February 3, 2020, which was subsequently
moved to January 29, 2020. On January 24, 2020 the Supreme Court granted our motion to stay the District Court
proceedings, pending the disposition of our petition for writ of certiorari, which was filed on January 31, 2020.
Archer conditionally cross petitioned for certiorari on an arbitration issue on March 2, 2020. On June 15, 2020, the
Supreme Court granted our petition for writ of certiorari, and denied Archer’s conditional petition for certiorari, and
thus the District Court proceedings remained stayed. After briefing from the parties and several amici, the case was
argued before the Supreme Court on December 8, 2020. On January 25, 2021, the Supreme Court dismissed the
writ of certiorari as improvidently granted. That action dissolved the stay the Supreme Court had previously
granted. The U.S. District Court for the Eastern District of Texas then set the case for trial, and jury selection was
scheduled to begin on June 1, 2021. Patterson and the Danaher Defendants settled with Archer and they have been
dismissed from the case with prejudice. Benco has agreed to settle the case with the plaintiff. Henry Schein and the
plaintiff have agreed to settle this matter for an amount that is not material to the Company and to dismiss the case
with prejudice.
On
May 29, 2018
, an amended complaint was filed in the MultiDistrict Litigation (“MDL”) proceeding In Re
National Prescription Opiate Litigation (MDL No. 2804; Case No. 17-md-2804) in an action entitled
Action”), in the U.S. District Court for the Northern District of Ohio,
.
In addition to the County of Summit Action,
named as a defendant in multiple lawsuits (currently less than one-hundred and fifty (
)), which
. These actions consist of some that have been consolidated
within the MDL and are currently abated for discovery purposes, and others which remain pending in state courts
and are proceeding independently and outside of the MDL. On October 9, 2020, the Circuit Court of the 17th
Judicial Circuit in and for Broward County, Florida, Case No. CACE19018882, granted Henry Schein’s motion to
dismiss the claims brought against it in the action filed by North Broward Hospital District et. al. The Florida court
gave plaintiffs until November 24, 2020 to replead their claims against Henry Schein. On January 8, 2021, Henry
Schein filed a motion to dismiss the Amended Complaint. By Order entered on March 24, 2021, the Circuit Court
of Washington County, Arkansas, Case No. 72-CV20-156, granted Henry Schein’s motion to dismiss the claims
brought against it in the action filed by Fayetteville Arkansas Hospital Company, LLC, et al. The Arkansas court
gave plaintiffs until forty-five (45) days from the date the court enters an order or orders deciding all other motions
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
)
30
to dismiss currently pending before the court, to replead their claims against Henry Schein. An action filed by
Tucson Medical Center et al. was previously scheduled for trial beginning on June 1, 2021 but the court has vacated
that trial date. At this time, the only cases set for trial are the actions filed by West Virginia University Hospitals,
Inc. et al., which is currently scheduled for a non-jury liability trial on plaintiffs’ public nuisance claims on
November 1, 2021, and DCH Health Care Authority, et al., which is currently scheduled for a liability jury trial on
plaintiffs’ public nuisance claims on July 18, 2022. Of Henry Schein’s 2020 revenue of approximately $
billion from continuing operations, sales of opioids represented less than
one-tenth of 1
a negligible part of our business. We intend to defend ourselves vigorously against these actions.
On
September 30, 2019
, the
, filed a putative class action complaint for violation of the federal securities laws
against
) in the U.S. District Court for the Eastern District of
New York, Case No. 2:19-cv-05530-FB-RLM. The complaint seeks to certify a class consisting of all persons and
entities who, subject to certain exclusions, purchased or otherwise acquired Covetrus common stock from February
8, 2019 through August 12, 2019. The case relates to the Animal Health Spin-off and Merger of the Henry Schein
Animal Health Business with Vets First Choice in February 2019.
management and supply-chain services, understated the costs of integrating the Henry Schein Animal Health
Business and Vets First Choice, understated Covetrus’s separation costs from Henry Schein, and understated the
impact on earnings from online competition and alternative distribution channels and from the loss of an allegedly
large customer in North America just before the Separation and Merger. The complaint seeks unspecified monetary
damages and a jury trial. Pursuant to the provisions of the PSLRA, the court appointed lead plaintiff and lead
counsel on December 23, 2019. Lead plaintiff filed a Consolidated Class Action Complaint on February 21, 2020.
Lead plaintiff added Steve Paladino, our Chief Financial Officer, as a defendant in the action. Lead plaintiff filed
an Amended Consolidated Class Action Complaint on May 21, 2020, in which it added a claim that Mr. Paladino is
a “control person” of Covetrus. We intend to defend ourselves vigorously against this action.
On
February 5, 2021
,
U.S. District Court for the Eastern District of New York, naming as defendants
and monetary relief. We intend to defend ourselves vigorously against this action. On April 8, 2021 the Court
entered an order staying the Garnsey action until forty-five (
) days after a decision is issued finally resolving the
motions to dismiss in the City of Hollywood Class Action.
From time to time, we may become a party to other legal proceedings, including, without limitation, product
liability claims, employment matters, commercial disputes, governmental inquiries and investigations (which may
in some cases involve our entering into settlement arrangements or consent decrees), and other matters arising out
of the ordinary course of our business. While the results of any legal proceeding cannot be predicted with certainty,
in our opinion none of these other pending matters are currently anticipated to have a material adverse effect on our
consolidated financial position, liquidity or results of operations.
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
)
31
Note 18 – Related Party Transactions
On February 7, 2019 (the “Distribution Date”), we completed the separation (the “Separation”) and subsequent
merger (“Merger”) of our animal health business (the “Henry Schein Animal Health Business”) with Direct Vet
Marketing, Inc. (d/b/a Vets First Choice, “Vets First Choice”). This was accomplished by a series of transactions
among us, Vets First Choice, Covetrus, Inc. (f/k/a HS Spinco, Inc. “Covetrus”), a wholly owned subsidiary of ours
prior to the Distribution Date, and HS Merger Sub, Inc., a wholly owned subsidiary of Covetrus (“Merger Sub”). In
connection with the Separation, we contributed, assigned and transferred to Covetrus certain applicable assets,
liabilities and capital stock or other ownership interests relating to the Henry Schein Animal Health Business. On
the Distribution Date, we received a tax-free distribution of $
financing incurred by Covetrus. On the Distribution Date and prior to the Animal Health Spin-off, Covetrus issued
shares of Covetrus common stock to certain institutional accredited investors for $
The proceeds of the Share Sale were paid to Covetrus and distributed to us. Subsequent to the Share Sale, we
distributed, on a pro rata basis, all of the shares of the common stock of Covetrus held by us to our stockholders of
record as of the close of business on January 17, 2019 (the “Animal Health Spin-off”).
December 2020. During the three months ended March 28, 2020, we recorded approximately $
for these services. Covetrus also purchased certain products from us pursuant to the transition services agreement,
which ended in December 2020. During the three months ended March 28, 2020, net sales to Covetrus were
approximately $
months ended March 27, 2021 and March 28, 2020, we recorded $
connection with costs related to this royalty agreement. As of March 27, 2021 and December 26, 2020, Henry
Schein One, LLC had a net receivable balance due from Internet Brands of $
respectively, comprised of amounts related to results of operations and the royalty agreement.
million and $
28, 2020, we purchased $
December 26, 2020, we had in aggregate $
million and $
32
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
Cautionary Note Regarding Forward-Looking Statements
In accordance with the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, we
provide the following cautionary remarks regarding important factors that, among others, could cause future results
to differ materially from the forward-looking statements, expectations and assumptions expressed or implied
herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of
future performance. These forward-looking statements involve known and unknown risks, uncertainties and other
factors that may cause our actual results, performance and achievements or industry results to be materially
different from any future results, performance or achievements expressed or implied by such forward-looking
statements. These statements are generally identified by the use of such terms as “may,” “could,” “expect,”
“intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate,” “to be,” “to make” or other comparable
terms. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in
the documents we file with the Securities and Exchange Commission (SEC), including our Annual Report on Form
10-K. Forward looking statements include the overall impact of the Novel Coronavirus Disease 2019 (COVID-19)
on the Company, its results of operations, liquidity, and financial condition (including any estimates of the impact
on these items), the rate and consistency with which dental and other practices resume or maintain normal
operations in the United States and internationally, expectations regarding personal protective equipment (“PPE”)
and COVID-19 related product sales and inventory levels and whether additional resurgences of the virus will
adversely impact the resumption of normal operations, the impact of restructuring programs as well as of any future
acquisitions, and more generally current expectations regarding performance in current and future periods.
Forward looking statements also include the (i) ability of the Company to make additional testing available, the
nature of those tests and the number of tests intended to be made available and the timing for availability, the nature
of the target market, as well as the efficacy or relative efficacy of the test results given that the test efficacy has not
been, or will not have been, independently verified under normal FDA procedures and (ii) potential for the
Company to distribute the COVID-19 vaccines and ancillary supplies.
Risk factors and uncertainties that could cause actual results to differ materially from current and historical results
include, but are not limited to: risks associated with COVID-19, as well as other disease outbreaks, epidemics,
pandemics, or similar wide spread public health concerns and other natural disasters or acts of terrorism; our
dependence on third parties for the manufacture and supply of our products; our ability to develop or acquire and
maintain and protect new products (particularly technology products) and technologies that achieve market
acceptance with acceptable margins; transitional challenges associated with acquisitions, dispositions and joint
ventures, including the failure to achieve anticipated synergies/benefits; financial and tax risks associated with
acquisitions, dispositions and joint ventures; certain provisions in our governing documents that may discourage
third-party acquisitions of us; effects of a highly competitive (including, without limitation, competition from third-
party online commerce sites) and consolidating market; the potential repeal or judicial prohibition on
implementation of the Affordable Care Act; changes in the health care industry; risks from expansion of customer
purchasing power and multi-tiered costing structures; increases in shipping costs for our products or other service
issues with our third-party shippers; general global macro-economic and political conditions, including
international trade agreements and potential trade barriers; failure to comply with existing and future regulatory
requirements; risks associated with the EU Medical Device Regulation; failure to comply with laws and regulations
relating to health care fraud or other laws and regulations; failure to comply with laws and regulations relating to
the confidentiality of sensitive personal information or standards in electronic health records or transmissions;
changes in tax legislation; litigation risks; new or unanticipated litigation developments and the status of litigation
matters; cyberattacks or other privacy or data security breaches; risks associated with our global operations; our
dependence on our senior management, as well as employee hiring and retention; and disruptions in financial
markets. The order in which these factors appear should not be construed to indicate their relative importance or
priority.
33
We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control
or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction
of actual results. We undertake no duty and have no obligation to update forward-looking statements.
Where You Can Find Important Information
We may disclose important information through one or more of the following channels: SEC filings, public
conference calls and webcasts, press releases, the investor relations page of our website (www.henryschein.com)
and the social media channels identified on the Newsroom page of our website.
Recent Developments
COVID-19 Pandemic
In March 2020, the World Health Organization declared COVID-19 a pandemic. The COVID-19 pandemic
negatively impacted the global economy, disrupted global supply chains and created significant volatility and
disruption of global financial markets. In response, many countries implemented business closures and restrictions,
stay-at-home and social distancing ordinances and similar measures to combat the pandemic, which significantly
impacted global business and dramatically reduced demand for dental products and certain medical products in the
second quarter of 2020.
Demand increased in the second half of 2020 and continued into the first quarter of 2021,
resulting in growth over the prior year driven by sales of PPE and COVID-19 related products.
Our consolidated financial statements reflect estimates and assumptions made by us that affect, among other things,
our goodwill, long-lived asset and indefinite-lived intangible asset valuation; inventory valuation; equity investment
valuation; assessment of the annual effective tax rate; valuation of deferred income taxes and income tax
contingencies; the allowance for doubtful accounts; hedging activity; vendor rebates; measurement of
compensation cost for certain share-based performance awards and cash bonus plans; and pension plan
assumptions. Due to the significant uncertainty surrounding the future impact of COVID-19, our judgments
regarding estimates and impairments could change in the future. In addition, the impact of COVID-19 had a
material adverse effect on our business, results of operations and cash flows in the second quarter of 2020. In the
latter half of the second quarter of 2020, dental and medical practices began to re-open worldwide, and continued to
do so during the second half of 2020. During the first quarter of 2021, patient traffic levels returned to levels
approaching pre-pandemic levels, although certain regions in the U.S. and internationally are experiencing an
increase in COVID-19 cases. There is an ongoing risk that the COVID-19 pandemic may again have a material
adverse effect on our business, results of operations and cash flows and may result in a material adverse effect on
our financial condition and liquidity. However, the extent of the potential impact cannot be reasonably estimated at
this time.
34
Executive-Level Overview
Henry Schein, Inc. is a solutions company for health care professionals powered by a network of people and
technology. We believe we are the world’s largest provider of health care products and services primarily to office-
based dental and medical practitioners, as well as alternate sites of care. We serve more than one million customers
worldwide including dental practitioners and laboratories and physician practices, as well as government,
institutional health care clinics and other alternate care clinics. We believe that we have a strong brand identity due
to our more than 88 years of experience distributing health care products.
We are headquartered in Melville, New York, employ more than 20,000 people (of which more than 9,500 are
based outside the United States) and have operations or affiliates in 31 countries and territories, including the
United States, Australia, Austria, Belgium, Brazil, Canada, Chile, China, the Czech Republic, France, Germany,
Hong Kong SAR, Ireland, Israel, Italy, Japan, Liechtenstein, Luxembourg, Malaysia, the Netherlands, New
Zealand, Poland, Portugal, Singapore, South Africa, Spain, Sweden, Switzerland, Thailand, United Arab Emirates
and the United Kingdom.
We have established strategically located distribution centers around the world to enable us to better serve our
customers and increase our operating efficiency. This infrastructure, together with broad product and service
offerings at competitive prices, and a strong commitment to customer service, enables us to be a single source of
supply for our customers’ needs. Our infrastructure also allows us to provide convenient ordering and rapid,
accurate and complete order fulfillment.
We conduct our business through two reportable segments: (i) health care distribution and (ii) technology and
value-added services. These segments offer different products and services to the same customer base.
The health care distribution reportable segment aggregates our global dental and medical operating segments. This
segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair
services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control
products and vitamins. Our global dental group serves office-based dental practitioners, dental laboratories, schools
and other institutions. Our global medical group serves office-based medical practitioners, ambulatory surgery
centers, other alternate-care settings and other institutions.
Our global technology and value-added services group provides software, technology and other value-added
services to health care practitioners. Our technology group offerings include practice management software
systems for dental and medical practitioners. Our value-added practice solutions include financial services on a
non-recourse basis, e-services, practice technology, network and hardware services, as well as continuing education
services for practitioners.
Industry Overview
In recent years, the health care industry has increasingly focused on cost containment. This trend has benefited
distributors capable of providing a broad array of products and services at low prices. It also has accelerated the
growth of HMOs, group practices, other managed care accounts and collective buying groups, which, in addition to
their emphasis on obtaining products at competitive prices, tend to favor distributors capable of providing
specialized management information support. We believe that the trend towards cost containment has the potential
to favorably affect demand for technology solutions, including software, which can enhance the efficiency and
facilitation of practice management.
Our operating results in recent years have been significantly affected by strategies and transactions that we
undertook to expand our business, domestically and internationally, in part to address significant changes in the
health care industry, including consolidation of health care distribution companies, health care reform, trends
toward managed care, cuts in Medicare and collective purchasing arrangements.
Our current and future results have been and could be impacted by the COVID-19 pandemic, the current economic
environment and continued economic and public health uncertainty. Since the onset of the COVID-19 pandemic in
early 2020, we have been carefully monitoring its impact on our global operations and have taken appropriate steps
35
to minimize the risk to our employees. We have seen and continue to see changes in demand trends for some of our
products and services as rates of infection fluctuate, new strains or mutations of COVID-19 emerge and spread,
vaccine uptake increases, governments adapt their approaches to combatting the virus, and local conditions change
across geographies. As a result, we expect to see continued volatility through at least the duration of the pandemic.
Industry Consolidation
The health care products distribution industry, as it relates to office-based health care practitioners, is fragmented
and diverse. The industry ranges from sole practitioners working out of relatively small offices to group practices
or service organizations ranging in size from a few practitioners to a large number of practitioners who have
combined or otherwise associated their practices.
Due in part to the inability of office-based health care practitioners to store and manage large quantities of supplies
in their offices, the distribution of health care supplies and small equipment to office-based health care practitioners
has been characterized by frequent, small quantity orders, and a need for rapid, reliable and substantially complete
order fulfillment. The purchasing decisions within an office-based health care practice are typically made by the
practitioner or an administrative assistant. Supplies and small equipment are generally purchased from more than
one distributor, with one generally serving as the primary supplier.
The trend of consolidation extends to our customer base. Health care practitioners are increasingly seeking to
partner, affiliate or combine with larger entities such as hospitals, health systems, group practices or physician
hospital organizations. In many cases, purchasing decisions for consolidated groups are made at a centralized or
professional staff level; however, orders are delivered to the practitioners’ offices.
We believe that consolidation within the industry will continue to result in a number of distributors, particularly
those with limited financial, operating and marketing resources, seeking to combine with larger companies that can
provide growth opportunities. This consolidation also may continue to result in distributors seeking to acquire
companies that can enhance their current product and service offerings or provide opportunities to serve a broader
customer base.
Our trend with regard to acquisitions and joint ventures has been to expand our role as a provider of products and
services to the health care industry. This trend has resulted in our expansion into service areas that complement our
existing operations and provide opportunities for us to develop synergies with, and thus strengthen, the acquired
businesses.
As industry consolidation continues, we believe that we are positioned to capitalize on this trend, as we believe we
have the ability to support increased sales through our existing infrastructure, although there can be no assurances
that we will be able to successfully accomplish this. We also have invested in expanding our sales/marketing
infrastructure to include a focus on building relationships with decision makers who do not reside in the office-
based practitioner setting.
As the health care industry continues to change, we continually evaluate possible candidates for merger and joint
venture or acquisition and intend to continue to seek opportunities to expand our role as a provider of products and
services to the health care industry. There can be no assurance that we will be able to successfully pursue any such
opportunity or consummate any such transaction, if pursued. If additional transactions are entered into or
consummated, we would incur merger and/or acquisition-related costs, and there can be no assurance that the
integration efforts associated with any such transaction would be successful. In response to the COVID-19
pandemic, we had taken a range of actions to preserve cash, including the temporary suspension of significant
acquisition activity. During the second half of 2020, as global conditions improved, we resumed our acquisition
strategy.
36
Aging Population and Other Market Influences
The health care products distribution industry continues to experience growth due to the aging population,
increased health care awareness, the proliferation of medical technology and testing, new pharmacology treatments
and expanded third-party insurance coverage, partially offset by the effects of unemployment on insurance
coverage. In addition, the physician market continues to benefit from the shift of procedures and diagnostic testing
from acute care settings to alternate-care sites, particularly physicians’ offices.
According to the U.S. Census Bureau’s International Data Base, in 2020 there were more than six and a half million
Americans aged 85 years or older, the segment of the population most in need of long-term care and elder-care
services. By the year 2050, that number is projected to nearly triple to approximately 19 million. The population
aged 65 to 84 years is projected to increase by approximately 36% during the same time period.
As a result of these market dynamics, annual expenditures for health care services continue to increase in the
United States. We believe that demand for our products and services will grow, while continuing to be impacted by
current and future operating, economic and industry conditions. The Centers for Medicare and Medicaid Services,
or CMS, published “National Health Expenditure Projections 2019-2028” indicating that total national health care
spending reached approximately $3.8 trillion in 2019, or 17.7% of the nation’s gross domestic product, the
benchmark measure for annual production of goods and services in the United States. Health care spending is
projected to reach approximately $6.2 trillion in 2028, approximately 19.7% of the nation’s projected gross
domestic product.
Government
Certain of our businesses involve the distribution, importation, exportation, marketing and sale of, and third party
payment for, pharmaceuticals and medical devices, and in this regard, we are subject to extensive local, state,
federal and foreign governmental laws and regulations, including as applicable to our wholesale distribution of
pharmaceuticals and medical devices, and as part of our specialty home medical supply business that distributes and
sells medical equipment and supplies directly to patients. The federal government and state governments have also
increased enforcement activity in the health care sector, particularly in areas of fraud and abuse, anti-bribery and
corruption, controlled substances handling, medical device regulations, and data privacy and security standards.
Government and private insurance programs fund a large portion of the total cost of medical care, and there have
been efforts to limit such private and government insurance programs, including efforts, thus far unsuccessful, to
seek repeal of the entire United States Patient Protection and Affordable Care Act, as amended by the Health Care
and Education Reconciliation Act, each enacted in March 2010, as amended. In addition, activities to control
medical costs, including laws and regulations lowering reimbursement rates for pharmaceuticals, medical devices,
and/or medical treatments or services, are ongoing. Many of these laws and regulations are subject to change and
their evolving implementation may impact our operations and our financial performance.
Our businesses are also generally subject to numerous other laws and regulations that could impact our financial
performance, including securities, antitrust, consumer protection, anti-bribery and anti-kickback, customer
interaction transparency, data privacy, data security, government contracting, price gouging, and other laws and
regulations.
Failure to comply with law or regulations could have a material adverse effect on our business. A more detailed
discussion of governmental laws and regulations is included in Management’s Discussion & Analysis, contained in
our Annual Report on Form 10-K for the fiscal year ended December 26, 2020, filed on February 17, 2021.
37
Results of Operations
The following table summarizes the significant components of our operating results and cash flows for the three
months ended March 27, 2021 and March 28, 2020 (in thousands):
Three Months Ended
March 27,
March 28,
2021
2020
Operating results:
Net sales
$
2,924,961
$
2,428,871
Cost of sales
2,034,110
1,682,857
Gross profit
890,851
746,014
Operating expenses:
Selling, general and administrative
657,992
567,362
Restructuring costs
2,931
4,787
Operating income
$
229,928
$
173,865
Other expense, net
$
(4,193)
$
(4,842)
Net income from continuing operations
174,928
133,847
Loss from discontinued operations
-
(282)
Net income attributable to Henry Schein, Inc.
165,997
130,261
Three Months Ended
March 27,
March 28,
2021
2020
Cash flows:
Net cash provided by operating activities from continuing operations
$
63,331
$
78,757
Net cash used in investing activities from continuing operations
(223,244)
(53,605)
Net cash provided by (used in) financing activities from continuing operations
(119,444)
491,608
Plans of Restructuring
On November 20, 2019, we committed to a contemplated initiative, intended to mitigate stranded costs associated
with the Animal Health Spin-off and to rationalize operations and to provide expense efficiencies. These activities
were originally expected to be completed by the end of 2020. In light of the changes to the business environment
brought on by the COVID-19 pandemic, we extended such activities to the end of 2021.
During the three months ended March 27, 2021 and March 28, 2020, we recorded restructuring costs of $2.9
million and $4.8 million, respectively. The restructuring costs for these periods included costs for severance
benefits and facility exit costs. The costs associated with these restructurings are included in a separate line item,
“Restructuring costs” within our consolidated statements of income.
We are currently unable in good faith to make a determination of an estimate of the amount or range of
amounts expected to be incurred in connection with these activities in 2021, both with respect to each major type of
cost associated therewith and with respect to the total cost, or an estimate of the amount or range of amounts that
will result in future cash expenditures.
38
Three Months Ended March 27, 2021 Compared to Three Months Ended March 28, 2020
Net Sales
Net sales for the three months ended March 27, 2021 and March 28, 2020 were as follows (in thousands):
March 27,
% of
March 28,
% of
Increase / (Decrease)
2021
Total
2020
Total
$
%
Health care distribution
(1)
Dental
$
1,788,928
61.2
%
$
1,475,076
60.7
%
$
313,852
21.3
%
Medical
993,037
33.9
800,688
33.0
192,349
24.0
2,781,965
95.1
2,275,764
93.7
506,201
22.2
Technology and value-added services
(2)
142,996
4.9
131,965
5.4
11,031
8.4
Total excluding Corporate TSA revenue
2,924,961
100.0
2,407,729
99.1
517,232
21.5
Corporate TSA revenue
(3)
-
-
21,142
0.9
(21,142)
-
Total
$
2,924,961
100.0
%
$
2,428,871
100.0
%
$
496,090
20.4
(1)
Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and
generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, personal protective equipment
and vitamins.
(2)
Consists of practice management software and other value-added products, which are distributed primarily to health care providers,
and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other
services.
(3)
Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered into in
connection with the Animal Health Spin-off, which ended in December 2020. See
information.
The 20.4% increase in net sales for the three months ended March 27, 2021 includes an increase of 18.2% in local
currency revenue (14.9% increase in internally generated revenue and 3.3% growth from acquisitions) and an
increase of 2.2% related to foreign currency exchange. During December 2020, our previous transition services
agreement (TSA) with Covetrus, in connection with the completion of the Animal-Health Spin-off, concluded.
Accordingly, we recorded no Corporate TSA revenues for the three months ended March 27, 2021. Sales for the
three months ended March 27, 2021 benefited from sales of PPE and COVID-19 related products of approximately
$457.5 million, an increase of approximately 189.5% versus the prior year.
The 21.3% increase in dental net sales for the three months ended March 27, 2021 includes an increase of 17.9% in
local currency revenue (13.7% increase in internally generated revenue and 4.2% growth from acquisitions) and an
increase of 3.4% related to foreign currency exchange. The 17.9% increase in local currency sales was attributable
to an increase in dental consumable merchandise sales of 18.3% (13.2% increase in internally generated revenue
and 5.1% growth from acquisitions) and an increase in dental equipment sales and service revenues of 16.1%,
(15.5% increase in internally generated revenue and 0.6% growth from acquisitions). The COVID-19 pandemic
had an adverse impact on prior year revenues when dental offices began closing or seeing a limited number of
patients beginning in mid-March of 2020. During the first quarter of 2021, patient traffic levels returned to levels
approaching pre-pandemic levels, thus contributing to growth in worldwide dental revenues. Additionally, global
dental sales for the three months ended March 27, 2021 benefited from sales of PPE and COVID-19 related
products of approximately $169.3 million, an increase of approximately 72.4% versus the prior year. Excluding
PPE and COVID-19 related products, the increase in internally generated local currency dental sales was 11.9%.
The 24.0% increase in medical net sales for the three months ended March 27, 2021 includes an increase of 23.7%
in local currency revenue (22.1% increase in internally generated revenue and 1.6% growth from acquisitions) and
an increase of 0.3% related to foreign currency exchange. Economic conditions relating to the COVID-19
pandemic had less of an impact on the performance of our medical group in the prior year in part due to continued
strong sales of PPE, such as masks, gowns and face shields, and other COVID-19 related products. Globally, our
medical business continued to benefit from sales of such PPE and other COVID-19 related products for the three
months ended March 27, 2021, recording net sales of $288.2 million, an increase of approximately 381.3%
compared to the prior year. Excluding sales of PPE and other COVID-19 related products, medical internal sales in
local currencies was down 6.8%, in part due to a mild influenza season that impacted diagnostic and consumable
merchandise sales, as well as from lower pharmaceutical sales.
39
The 8.4% increase in technology and value-added services net sales for the three months ended March 27, 2021
includes an increase of 7.0% local currency revenue (3.6% increase in internally generated revenue and 3.4%
growth from acquisitions) and an increase of 1.4% related to foreign currency exchange. Sales growth was driven
by our practice management business, as well as strong financial services revenue, which benefited from dental
equipment sales growth. During the quarter ended March 27, 2021, the trend for transactional software revenues
improved compared to the prior year, as more patients visited dental practices worldwide.
Gross Profit
Gross profit and gross margin percentages by segment and in total for the three months ended March 27, 2021 and
March 28, 2020 were as follows (in thousands):
March 27,
Gross
March 28,
Gross
Increase / (Decrease)
2021
Margin %
2020
Margin %
$
%
Health care distribution
$
789,984
28.4
%
$
653,316
28.7
%
$
136,668
20.9
%
Technology and value-added services
100,867
70.5
92,085
69.8
8,782
9.5
Total excluding Corporate TSA revenues
890,851
30.5
745,401
31.0
145,450
19.5
Corporate TSA revenues
-
-
613
2.9
(613)
-
Total
$
890,851
30.5
$
746,014
30.7
$
144,837
19.4
As a result of different practices of categorizing costs associated with distribution networks throughout our
industry, our gross margins may not necessarily be comparable to other distribution companies. Additionally, we
realize substantially higher gross margin percentages in our technology segment than in our health care distribution
segment. These higher gross margins result from being both the developer and seller of software products and
services, as well as certain financial services. The software industry typically realizes higher gross margins to
recover investments in research and development.
During December 2020, our previous transition services agreement with Covetrus, in connection with the
completion of the Animal-Health Spin-off, concluded. Under this agreement, Covetrus had agreed to purchase
certain products from us at a mark-up that ranged from 3% to 6% of our product cost to cover handling costs.
Within our health care distribution segment, gross profit margins may vary from one period to the next. Changes in
the mix of products sold as well as changes in our customer mix have been the most significant drivers affecting
our gross profit margin. For example, sales of pharmaceutical products are generally at lower gross profit margins
than other products. Conversely, sales of our private label products achieve gross profit margins that are higher than
average. With respect to customer mix, sales to our large-group customers are typically completed at lower gross
margins due to the higher volumes sold as opposed to the gross margin on sales to office-based practitioners, who
normally purchase lower volumes at greater frequencies.
Health care distribution gross profit increased $136.7 million, or 20.9%, for the three months ended March 27, 2021
compared to the prior year period, due primarily to the increase in net sales discussed above. Health care
distribution gross profit margin decreased to 28.4% for the three months ended March 27, 2021 from 28.7% for the
comparable prior year period due to adjustments recorded for PPE inventory and COVID-19 related products, as
well as influenza diagnostic kits, caused by volatility of pricing and demand experienced during the quarter. Such
conditions may recur and adversely impact gross profit margins in future periods, although we do not expect further
material inventory adjustments in 2021. The overall increase in our health care distribution gross profit is
attributable to an increase of $120.5 million from internally generated revenue and $27.2 million increase in gross
profit from acquisitions, partially offset by an $11.0 million decline in gross profit due to the decrease in the gross
margin rates.
40
Technology and value-added services gross profit increased $8.8 million, or 9.5%, for the three months ended
March 27, 2021 compared to the prior year period. The overall increase in our Technology and value-added
services gross profit is attributable to a $4.5 million increase in internally generated revenue, $4.2 million additional
gross profit from acquisitions, and an increase of $0.1 million from gross margin rates. Technology and value-
added services gross profit margin increased to 70.5% for the three months ended March 27, 2021 from 69.8% for
the comparable prior year period primarily due to an increase in the volume of our transactional revenue from
eClaims and credit card processing.
Selling, General and Administrative
Selling, general and administrative expenses by segment and in total for the three months ended March 27, 2021
and March 28, 2020 were as follows (in thousands):
% of
% of
March 27,
Respective
March 28,
Respective
Increase
2021
Net Sales
2020
Net Sales
$
%
Health care distribution
$
592,052
21.3
%
$
505,762
22.2
%
$
86,290
17.1
%
Technology and value-added services
68,871
48.2
66,387
50.3
2,484
3.7
Total
$
660,923
22.6
$
572,149
23.6
$
88,774
15.5
Selling, general and administrative expenses (including restructuring costs in the three months ended March 27,
2021 and March 28, 2020) increased $88.8 million, or 15.5%, for the three months ended March 27, 2021 from the
comparable prior year period. The $86.3 million increase in selling, general and administrative expenses within our
health care distribution segment for the three months ended March 27, 2021 as compared to the prior year period
was attributable to an increase of $64.8 million of operating costs (including $12.8 million of settlement and
litigation costs), an increase of $23.3 million of additional costs from acquired companies, partially offset by a
decrease of $1.8 million in restructuring costs. The $2.5 million increase in selling, general and administrative
expenses within our technology and value-added services segment for the three months ended March 27, 2021 as
compared to the prior year period was attributable to an increase of $3.5 million of additional costs from acquired
companies, partially offset by a decrease of $1.0 million of operating costs. As a percentage of net sales, selling,
general and administrative expenses decreased to 22.6% from 23.6% for the comparable prior year period.
As a component of total selling, general and administrative expenses, selling expenses increased $12.9 million, or
3.5% to $384.7 million, for the three months ended March 27, 2021 from the comparable prior year period. As a
percentage of net sales, selling expenses decreased to 13.2% from 15.3% for the comparable prior year period.
As a component of total selling, general and administrative expenses, general and administrative expenses
increased $75.9 million, or 37.9% to $276.2 million, for the three months ended March 27, 2021 from the
comparable prior year period, primarily due to an increase in payroll and payroll related costs. As a percentage of
net sales, general and administrative expenses increased to 9.4% from 8.2% for the comparable prior year period.
Our selling, general and administrative expenses for the three months ended March 28, 2020 were affected by
certain estimates we made due to the adverse business environment brought on by the COVID-19 pandemic. For
example, in the prior-year quarter we recorded incremental bad debt reserves of approximately $10 million for our
global dental business. We also recognized a net credit of approximately $17.5 million in stock-based compensation
expense during the prior-year quarter as we had estimated that no performance shares granted in 2018, 2019 or
2020 would ultimately vest. In contrast, for the three months ended March 27, 2021, we recorded $12.8 million in
stock-based compensation expense. Additionally, in the prior-year quarter we recorded total impairment charges of
approximately $6.1 million during the quarter related to prepaid royalty expenses and a customer relationship
intangible asset. We recorded no such impairment charges in the three months ended March 27, 2021.
41
Other Expense, Net
Other expense, net, for the three months ended March 27, 2021 and March 28, 2020 was as follows (in thousands):
March 27,
March 28,
Variance
2021
2020
$
%
Interest income
$
1,983
$
3,190
$
(1,207)
(37.8)
%
Interest expense
(6,485)
(7,812)
1,327
17.0
Other, net
309
(220)
529
240.5
Other expense, net
$
(4,193)
$
(4,842)
$
649
13.4
Interest income decreased $1.2 million primarily due to lower investment and late fee income. Interest expense
decreased $1.3 million primarily due to decreased borrowings under our bank credit lines as well as lower interest
rates.
Income Taxes
For the three months ended March 27, 2021, our effective tax rate was 25.1% compared to 22.4% for the prior year
period. The difference between our effective tax rate and the federal statutory tax rate for the three months ended
March 27, 2021, was primarily due to state and foreign income taxes and interest expense. The difference between
our effective tax rate and the federal statutory tax rate for the three months ended March 28, 2020 primarily relates
to state and foreign income taxes and interest expense as well as tax charges and credits associated with legal entity
reorganizations outside the United States.
Liquidity and Capital Resources
Our principal capital requirements have included funding of acquisitions, purchases of additional noncontrolling
interests, repayments of debt principal, the funding of working capital needs, purchases of fixed assets and
repurchases of common stock (which had been temporarily suspended, but were resumed during the three months
ended March 27, 2021). Working capital requirements generally result from increased sales, special inventory
forward buy-in opportunities and payment terms for receivables and payables. Historically, sales have tended to be
stronger during the second half of the year and special inventory forward buy-in opportunities have been most
prevalent just before the end of the year, and have caused our working capital requirements to be higher from the
end of the third quarter to the end of the first quarter of the following year.
The pandemic and the governmental responses to it had a material adverse effect on our cash flows in the second
quarter of 2020. In the latter half of the second quarter of 2020 and continuing through year-end, dental and
medical practices began to re-open worldwide. During the first quarter of 2021, patient traffic levels returned to
levels approaching pre-pandemic levels, although certain regions in the U.S. and internationally are experiencing an
increase in COVID-19 cases. There is an ongoing risk that the COVID-19 pandemic may again have a material
adverse effect on our business, results of operations and cash flows and may result in a material adverse effect on
our financial condition and liquidity. However, the extent of the potential impact cannot be reasonably estimated at
this time.
We finance our business primarily through cash generated from our operations, revolving credit facilities and debt
placements. Our ability to generate sufficient cash flows from operations is dependent on the continued demand of
our customers for our products and services, and access to products and services from our suppliers.
Our business requires a substantial investment in working capital, which is susceptible to fluctuations during the
year as a result of inventory purchase patterns and seasonal demands. Inventory purchase activity is a function of
sales activity, special inventory forward buy-in opportunities and our desired level of inventory. We anticipate
future increases in our working capital requirements.
We finance our business to provide adequate funding for at least 12 months. Funding requirements are based on
forecasted profitability and working capital needs, which, on occasion, may change. Consequently, we may change
our funding structure to reflect any new requirements.
42
We believe that our cash and cash equivalents, our ability to access private debt markets and public equity markets,
and our available funds under existing credit facilities provide us with sufficient liquidity to meet our currently
foreseeable short-term and long-term capital needs. We have no off-balance sheet arrangements.
Net cash from continuing operations provided by operating activities was $63.3 million for the three months ended
March 27, 2021, compared to net cash from continuing operations provided by operating activities of $78.8 million
for the comparable prior year period. The net change of $15.4 million was primarily attributable to increased
working capital requirements, specifically an increase in inventories due to stocking of PPE and other COVID-19
related products, partially offset by decreased accounts receivable due to lower days sales outstanding. The effect
on operating cash flows from the increased working capital requirements was partially offset by higher net income.
Net cash from continuing operations used in investing activities was $223.2 million for the three months ended
March 27, 2021, compared to $53.6 million for the comparable prior year period. The net change of $169.6 million
was attributable to increased payments for equity investments and business acquisitions.
Net cash from continuing operations used in financing activities was $119.4 million for the three months ended
March 27, 2021, compared to net cash provided by financing activities of $491.6 million for the comparable prior
year period. The net change of $611.1 million was primarily due to decreased net proceeds from bank borrowings.
The following table summarizes selected measures of liquidity and capital resources (in thousands):
March 27,
December 26,
2021
2020
Cash and cash equivalents
$
144,538
$
421,185
Working capital
1,447,857
1,508,313
Debt:
Bank credit lines
$
67,415
$
73,366
Current maturities of long-term debt
111,176
109,836
Long-term debt
506,461
515,773
Total debt
$
685,052
$
698,975
Leases:
Current operating lease liabilities
$
68,580
$
64,716
Non-current operating lease liabilities
248,624
238,727
(1)
At March 27, 2021 and December 26, 2020, there were no trade accounts receivable that were restricted to settle obligations of this VIE,
nor were there liabilities of the VIE where the creditors have recourse to us.
Our cash and cash equivalents consist of bank balances and investments in money market funds representing
overnight investments with a high degree of liquidity.
Accounts receivable days sales outstanding and inventory turns
Our accounts receivable days sales outstanding from operations decreased to 42.8 days as of March 27, 2021 from
45.9 days as of March 28, 2020. During the three months ended March 27, 2021, we wrote off approximately $3.3
million of fully reserved accounts receivable against our trade receivable reserve. Our inventory turns from
operations increased to 5.2 as of March 27, 2021 from 4.9 as of March 28, 2020. Our working capital accounts
may be impacted by current and future economic conditions.
43
Bank Credit Lines
Bank credit lines consisted of the following:
March 27,
December 26,
2021
2020
Revolving credit agreement
$
-
$
-
Other short-term bank credit lines
67,415
73,366
Total
$
67,415
$
73,366
Revolving Credit Agreement
On April 18, 2017, we entered into a $750 million revolving credit agreement (the “Credit Agreement”), which
matures in April 2022. The interest rate is based on the USD LIBOR plus a spread based on our leverage ratio at
the end of each financial reporting quarter. We expect most LIBOR rates to be discontinued immediately after
December 31, 2021, while the remaining LIBOR rates will be discontinued immediately after June 30, 2023, which
will require an amendment to our debt agreements to reflect a new reference rate. We do not expect the
discontinuation of LIBOR as a reference rate in our debt agreements to have a material adverse effect on our
financial position or to materially affect our interest expense. The Credit Agreement also requires, among other
things, that we maintain maximum leverage ratios. Additionally, the Credit Agreement contains customary
representations, warranties and affirmative covenants as well as customary negative covenants, subject to
negotiated exceptions on liens, indebtedness, significant corporate changes (including mergers), dispositions and
certain restrictive agreements. As of March 27, 2021, and December 26, 2020, we had no borrowings on this
revolving credit facility. As of March 27, 2021, and December 26, 2020, there were $9.3 million and $9.5 million
of letters of credit, respectively, provided to third parties under the credit facility.
On April 17, 2020, we amended the Credit Agreement to, among other things, (i) modify the financial covenant
from being based on total leverage ratio to net leverage ratio, (ii) adjust the pricing grid to reflect the net leverage
ratio calculation, and (iii) increase the maximum maintenance leverage ratio through March 31, 2021.
364-Day Credit Agreement
On March 4, 2021 we repaid the outstanding obligations and terminated the lender commitments under our $700
million 364-day credit agreement which was entered into on April 17, 2020. This facility was originally scheduled
to mature on April 16, 2021.
Other Short-Term Credit Lines
As of March 27, 2021 and December 26, 2020, we had various other short-term bank credit lines available, of
which $67.4 million and $73.4 million, respectively, were outstanding. At March 27, 2021 and December 26,
2020, borrowings under all of these credit lines had a weighted average interest rate of 4.52% and 4.14%,
respectively.
44
Long-term debt
Long-term debt consisted of the following:
March 27,
December 26,
2021
2020
Private placement facilities
$
606,355
$
613,498
Note payable
-
1,554
Various collateralized and uncollateralized loans payable with interest,
in varying installments through 2023 at interest rates
ranging from 2.45% to 4.27% at March 27, 2021 and
ranging from 2.62% to 4.27% at December 26, 2020
5,969
4,596
Finance lease obligations (see Note 7)
5,313
5,961
Total
617,637
625,609
Less current maturities
(111,176)
(109,836)
Total long-term debt
$
506,461
$
515,773
Private Placement Facilities
Our private placement facilities, with three insurance companies, have a total facility amount of $1 billion, and are
available on an uncommitted basis at fixed rate economic terms to be agreed upon at the time of issuance, from
time to time through June 23, 2023. The facilities allow us to issue senior promissory notes to the lenders at a fixed
rate based on an agreed upon spread over applicable treasury notes at the time of issuance. The term of each
possible issuance will be selected by us and can range from five to 15 years (with an average life no longer than 12
years). The proceeds of any issuances under the facilities will be used for general corporate purposes, including
working capital and capital expenditures, to refinance existing indebtedness and/or to fund potential acquisitions.
The agreements provide, among other things, that we maintain certain maximum leverage ratios, and contain
restrictions relating to subsidiary indebtedness, liens, affiliate transactions, disposal of assets and certain changes in
ownership. These facilities contain make-whole provisions in the event that we pay off the facilities prior to the
applicable due dates.
On March 5, 2021, we amended the private placement facilities to, among other things, (a) modify the financial
covenant from being based on a net leverage ratio to a total leverage ratio and (b) restore the maximum
maintenance total leverage ratio to 3.25x and remove the 1.00% interest rate increase triggered if the net leverage
ratio were to exceed 3.0x.
The components of our private placement facility borrowings as of March 27, 2021 are presented in the following
table (in thousands):
Amount of
Borrowing
Borrowing
Date of Borrowing
Outstanding
Rate
Due Date
January 20, 2012
$
7,143
3.09
%
January 20, 2022
January 20, 2012
50,000
3.45
January 20, 2024
December 24, 2012
50,000
3.00
December 24, 2024
June 2, 2014
100,000
3.19
June 2, 2021
June 16, 2017
100,000
3.42
June 16, 2027
September 15, 2017
100,000
3.52
September 15, 2029
January 2, 2018
100,000
3.32
January 2, 2028
September 2, 2020
100,000
2.35
September 2, 2030
Less: Deferred debt issuance costs
(788)
$
606,355
(1) Annual repayments of approximately $7.1 million for this borrowing commenced on January 20, 2016.
45
U.S. Trade Accounts Receivable Securitization
We have a facility agreement with a bank, as agent, based on the securitization of our U.S. trade accounts
receivable that is structured as an asset-backed securitization program with pricing committed for up to three years.
Our current facility, which has a purchase limit of $350 million, was scheduled to expire on April 29, 2022. On
June 22, 2020, the expiration date for this facility was extended to June 12, 2023 and was amended to adjust certain
covenant levels for 2020. As of March 27, 2021 and December 26, 2020, there were no borrowings outstanding
under this securitization facility. At March 27, 2021, the interest rate on borrowings under this facility was based
on the asset-backed commercial paper rate of 0.18% plus 0.95%, for a combined rate of 1.13%. At December 26,
2020, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of
0.22% plus 0.95%, for a combined rate of 1.17%.
If our accounts receivable collection pattern changes due to customers either paying late or not making payments,
our ability to borrow under this facility may be reduced.
We are required to pay a commitment fee of 25 to 45 basis points depending upon program utilization.
Leases
We have operating and finance leases for corporate offices, office space, distribution and other facilities, vehicles,
and certain equipment. Our leases have remaining terms of less than one year to approximately 15 years, some of
which may include options to extend the leases for up to 10 years. As of March 27, 2021, our right-of-use assets
related to operating leases were $301.8 million and our current and non-current operating lease liabilities were
$68.6 million and $248.6 million, respectively.
Stock Repurchases
On March 8, 2021, we announced the reinstatement of our share repurchase program.
From March 3, 2003 through March 27, 2021, we repurchased $3.7 billion, or 76,888,531 shares, under our
common stock repurchase programs, with $112.6 million available as of March 27, 2021 for future common stock
share repurchases.
Redeemable Noncontrolling Interests
Some minority stockholders in certain of our subsidiaries have the right, at certain times, to require us to acquire
their ownership interest in those entities at fair value. Accounting Standards Codification Topic 480-10 is
applicable for noncontrolling interests where we are or may be required to purchase all or a portion of the
outstanding interest in a consolidated subsidiary from the noncontrolling interest holder under the terms of a put
option contained in contractual agreements. The components of the change in the redeemable noncontrolling
interests for the three months ended March 27, 2021 and the year ended December 26, 2020 are presented in the
following table:
March 27,
December 26,
2021
2020
Balance, beginning of period
$
327,699
$
287,258
Decrease in redeemable noncontrolling interests due to
redemptions
-
(17,241)
Increase in redeemable noncontrolling interests due to business
acquisitions
85,037
28,387
Net income attributable to redeemable noncontrolling interests
7,053
13,363
Dividends declared
(6,237)
(12,631)
Effect of foreign currency translation loss attributable to
redeemable noncontrolling interests
(6,173)
(4,279)
Change in fair value of redeemable securities
45,520
32,842
Balance, end of period
$
452,899
$
327,699
46
Changes in the estimated redemption amounts of the noncontrolling interests subject to put options are adjusted at
each reporting period with a corresponding adjustment to Additional paid-in capital. Future reductions in the
carrying amounts are subject to a floor amount that is equal to the fair value of the redeemable noncontrolling
interests at the time they were originally recorded. The recorded value of the redeemable noncontrolling interests
cannot go below the floor level. These adjustments do not impact the calculation of earnings per share.
Additionally, some prior owners of such acquired subsidiaries are eligible to receive additional purchase price cash
consideration if certain financial targets are met. Any adjustments to these accrual amounts are recorded in our
consolidated statements of income. For the three months ended March 27, 2021 and March 28, 2020, there were no
material adjustments recorded in our consolidated statements of income relating to changes in estimated contingent
purchase price liabilities.
Noncontrolling Interests
Noncontrolling interests represent our less than 50% ownership interest in an acquired subsidiary. Our net income
is reduced by the portion of the subsidiaries net income that is attributable to noncontrolling interests.
Critical Accounting Policies and Estimates
There have been no material changes in our critical accounting policies and estimates from those disclosed in Item
7 of our Annual Report on Form 10-K for the year ended December 26, 2020, except accounting policies adopted
as of December 27, 2020, which are discussed in
under Item 1.
Our financial results for the three months ended March 27, 2021 were affected by certain estimates we made due to
the adverse business environment brought on by the COVID-19 pandemic. For example, in the quarter ended
March 28, 2020 we recorded incremental bad debt reserves of approximately $10.0 million for our global dental
business. During the quarter ended March 28, 2020, we also recognized a net credit of approximately $17.5 million
in stock-based compensation expense due to our estimate that no performance shares granted in 2018, 2019 or 2020
would ultimately vest. In contrast, for the three months ended March 27, 2021, we recorded $12.8 million in stock-
based compensation expense. Additionally in the quarter ended March 28, 2020, we recorded total impairment
charges of approximately $6.1 million related to prepaid royalty expenses and a customer relationship intangible
asset. We had no material impairment charges in the quarter ended March 27, 2021. Although our selling, general
and administrative expenses for the three months ended March 27, 2021 represent management's best estimates and
assumptions that affect the reported amounts, our judgment could change in the future due to the significant
uncertainty surrounding the macroeconomic effect of the COVID-19 pandemic.
Accounting Standards Update
For a discussion of accounting standards updates that have been adopted or will be adopted, see
to the Consolidated Financial Statements included under Item 1.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
There have been no material changes in our exposure to market risk from that disclosed in Item 7A of our Annual
Report on Form 10-K for the year ended December 26, 2020.
47
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of management, including our principal executive officer and
principal financial officer, we evaluated the effectiveness of the design and operation of our disclosure controls and
procedures as of the end of the period covered by this quarterly report as such term is defined in Rules 13a-15(e)
and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based
on this evaluation, our management, including our principal executive officer and principal financial officer,
concluded that our disclosure controls and procedures were effective as of March 27, 2021, to ensure that all
material information required to be disclosed by us in reports that we file or submit under the Exchange Act is
accumulated and communicated to them as appropriate to allow timely decisions regarding required disclosure and
that all such information is recorded, processed, summarized and reported within the time periods specified in the
SEC’s rules and forms.
Changes in Internal Control over Financial Reporting
The combination of acquisitions and continued acquisition integrations undertaken
during the quarter and carried
over from prior quarters, as well as changes to the operating methods of some of our internal controls over financial
reporting due to the COVID-19 pandemic, when considered in the aggregate, represents a material change in our
internal control over financial reporting.
During the quarter ended March 27, 2021, we completed the acquisition of dental and medical businesses in North
America and Europe with approximate aggregate annual revenues of approximately $354 million. In addition,
post-acquisition integration related activities continued for our North American medical and global dental
businesses acquired during prior quarters, representing aggregate annual revenues of approximately $299
million. These acquisitions, the majority of which utilize separate information and financial accounting systems,
have been included in our consolidated financial statements since their respective dates of acquisition.
All acquisitions and continued acquisition integrations involve necessary and appropriate change-management
controls that are considered in our quarterly assessment of the design and operating effectiveness of our internal
control over financial reporting.
In addition, as a result of a combination of continued governmental imposed and Company directed closures of
some of our facilities due to the COVID-19 pandemic, we have had to maintain a number of changes to the
operating methods of some of our internal controls. For example, moving from manual sign-offs and in-person
meetings to electronic sign-offs and electronic communications such as email and telephonic or video conference
due to out-of-office working arrangements. However, the design of our internal control framework and objectives
over financial reporting remains unchanged and we do not believe that these changes have materially affected, or
are reasonably likely to materially affect, the effectiveness of our internal control over financial reporting.
Limitations of the Effectiveness of Internal Control
A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance
that the objectives of the internal control system are met. Because of the inherent limitations of any internal control
system, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company
have been detected.
48
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
For a discussion of Legal Proceedings, see
Statements included under Item 1.
ITEM 1A. RISK FACTORS
There have been no material changes from the risk factors disclosed in Part 1, Item 1A, of our Annual Report on
Form 10-K for the year ended December 26, 2020.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Purchases of equity securities by the issuer
Our share repurchase program announced on March 3, 2003
, originally allowed us to repurchase up to two million
shares pre-stock splits (eight million shares post-stock splits) of our common stock, which represented
approximately 2.3% of the shares outstanding at the commencement of the program. Subsequent additional
increases totaling $3.7 billion, authorized by our Board of Directors, to the repurchase program provide for a total
of $3.8 billion of shares of our common stock to be repurchased under this program.
On March 8, 2021, we announced the reinstatement of our share repurchase program.
As of March 27, 2021, we had repurchased approximately $3.7 billion of common stock (76,888,531 shares) under
these initiatives, with $112.6 million available for future common stock share repurchases.
The following table summarizes repurchases of our common stock under our stock repurchase program during the
fiscal quarter ended March 27, 2021.
Total Number
Maximum Number
Total
of Shares
of Shares
Number
Average
Purchased as Part
that May Yet
of Shares
Price Paid
of Our Publicly
Be Purchased Under
Fiscal Month
Purchased (1)
Per Share
Announced Program
Our Program (2)
12/27/20 through 1/30/2021
-
$
-
-
3,055,600
1/31/21 through 2/27/2021
-
-
-
3,253,214
2/28/21 through 3/27/2021
1,325,242
66.90
1,325,242
1,655,664
1,325,242
1,325,242
(1) All repurchases were executed in the open market under our existing publicly announced authorized program.
(2) The maximum number of shares that may yet be purchased under this program is determined at the end of each month based on the
closing price of our common stock at that time. This table excludes shares withheld from employees to satisfy minimum tax withholding
requirements for equity-based transactions.
49
ITEM 6. EXHIBITS
.
2021.)
.
2021.)
.
2021.)
.
101.INS
Inline XBRL Instance Document - the instance document does not appear in the
Interactive Data File because its XBRL tags are embedded within the Inline
XBRL document+
101.SCH
Inline XBRL Taxonomy Extension Schema Document+
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase Document+
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase Document+
101.LAB
Inline XBRL Taxonomy Extension Label Linkbase Document+
101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase Document+
104
The cover page of Henry Schein, Inc.’s Quarterly Report on Form 10-Q for the
quarter ended March 27, 2021, formatted in Inline XBRL (included within
Exhibit 101 attachments).+
+ Filed or furnished herewith.
** Indicates management contract or compensatory plan or agreement.
50
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to
be signed on its behalf by the undersigned thereunto duly authorized.
Henry Schein, Inc.
(Registrant)
By: /s/ Steven Paladino
Steven Paladino
Executive Vice President and
Chief Financial Officer
(Authorized Signatory and Principal Financial
and Accounting Officer)
Dated: May 4, 2021
1
Form 3
3/21
Exhibit 10.2
FORM OF
2021 SPECIAL PANDEMIC RECOGNITION AWARD
RESTRICTED STOCK
UNIT AGREEMENT
PURSUANT TO THE
HENRY SCHEIN, INC. 2020 STOCK INCENTIVE PLAN
(AS AMENDED AND RESTATED EFFECTIVE AS OF MAY 21, 2020)
THIS AGREEMENT (the “Agreement”) is made as of [Grant Date] (the “Grant Date”), by and between Henry Schein, Inc. (the “Company”) and
[Participant Name] (the “Participant”). Additional country-specific terms and conditions that govern the grant made hereunder are attached hereto on Annex 1,
which terms and conditions are incorporated by reference herein and made a part of the Agreement.
W I T N E S S E T H:
WHEREAS
, the Company has adopted the Henry Schein, Inc. 2020 Stock Incentive Plan (as amended and restated effective as of May 21, 2020),
as amended from time to time (the “Plan”) (a copy of which is on file with the Company’s Corporate Human Resources Department and is available for
Participant to review upon request at reasonable intervals as determined by the Company), which is administered by a Committee appointed by the Company’s
Board of Directors (the “Committee”);
WHEREAS,
WHEREAS
, the shares of the Company’s common stock are traded on the Nasdaq Stock Market under the symbol “HSIC”; and
WHEREAS
, the Participant is a Key Employee of the Company or a Subsidiary.
NOW, THEREFORE
, for and in consideration of the mutual promises herein contained, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties agree as follows:
1.
Grant of Restricted Stock Units
.
Subject to the restrictions and other conditions set forth herein, in the Plan and Annex 1, the Committee has authorized this grant of [Shares
Granted] Restricted Stock Units to the Participant on the Grant Date.
2.
Vesting and Payment
.
(a)
Except as set forth in Sections 2(c) and 2(d), fifty percent (50%) of the Restricted Stock Units shall vest on the first
anniversary of the Grant Date, and fifty percent (50%) of the Restricted Stock Units shall vest on the second anniversary of the Grant Date (each, a “Scheduled
Payment Date”); in each case, provided that the Participant has not had a Termination of Employment at any time prior to
the applicable Scheduled Payment
Date.
(b)
Except as set forth in Section 2(c), there shall be no proportionate or partial vesting in the periods prior to the vesting date
and all vesting shall occur only on the vesting date; provided that no Termination of Employment has occurred prior to such date.
(c)
The Restricted Stock Units shall vest on a pro-rated basis upon the Participant’s Retirement, unless otherwise provided
expressly in a written agreement between the Participant and the Company (or a Subsidiary). For purposes of this Section 2(c), the Participant shall qualify for
“Retirement” if (i) the Participant’s age (minimum 55) plus years of service with the Company and its Subsidiaries equal or exceed 70, (ii) the Participant has
provided written notice of the Participant’s retirement to the Company at least 30 days prior to the date of such retirement, and (iii) no Termination of
Employment has occurred prior to the date of such retirement. For purposes of determining the age and service requirement under Section 2(c)(i), the
Participant’s age and years of service shall be determined by the Participant’s most recent birthday and employment anniversary, respectively. For purposes of
this Section 2(c), vesting on a pro-rated basis shall be calculated as the difference between (x) the product of (A) the number of Restricted Stock Units set forth
under Section 1 and (B) a fraction, the numerator of which is the number of days from the Grant Date to the date of the Participant’s Retirement and the
denominator of which is the number of days from the Grant Date to the second anniversary of the Grant Date, minus (y) the number of Restricted Stock Units
that have previously vested as of the date of the Participant’s Retirement (if any).
(d)
The Restricted Stock Units shall become fully vested on the earliest of (i) a Termination of Employment by the Company (or
a Subsidiary) without Cause occurring within the 2-year period following a Change of Control, (ii) the Participant’s Disability and (iii) the Participant’s death;
provided that no Termination of Employment has occurred prior to any such event, unless otherwise provided expressly in a written agreement between the
Participant and the Company (or a Subsidiary). For purposes of this Agreement, “Cause” shall have the meaning set forth in Section 7(b) of the Plan, but shall
also include any breach by Participant of any agreement with the Company or any of its Subsidiaries. For purposes of this Agreement, a “Change of Control”
shall mean a Change of Control as defined in the Plan. For purposes of this Agreement, “Disability” shall mean the approval of, and receiving benefits for,
long term disability by the disability insurance carrier under the Company’s (or if applicable, Subsidiary’s) long term disability plan.
(e)
The Participant shall be entitled to receive one share of Common Stock with respect to one vested Restricted Stock Unit. The
Participant shall be paid one share of Common Stock with respect to each vested Restricted Stock Unit within thirty (30) days of the Scheduled Payment Date;
except that, in the event of (i) Retirement, (ii) a Termination of Employment by the Company (or a Subsidiary) without Cause occurring within the 2-year
period following a Change of Control, (iii) death or (iv) Disability, the Participant shall be paid within thirty (30) days of such Retirement, Termination of
Employment, death or Disability, subject to Section 18 set forth in Annex 1 to the extent applicable, including with respect to a Participant who qualifies for
Retirement at any time following the Grant Date.
3.
Forfeiture and Recoupment.
(a)
Subject to Section 2 above, all unvested Restricted Stock Units will be forfeited on the Participant’s Termination of
Employment.
(b)
Notwithstanding anything herein or in the Plan to the contrary, the grant of Restricted Stock Units (including any dividends
credited thereupon) provided for under this Agreement is conditioned on the Participant not engaging in any Competitive Activity (as defined below) from the
date that is twelve (12) months prior to the applicable settlement date set forth in Section 2(a) or Section 2(e) above, as applicable (such applicable settlement
date, the “Payment Date”) through the first anniversary of such Payment Date. If, on or after the date that is twelve (12) months prior to the Payment Date but
prior to the Payment Date, the Participant engages in a Competitive Activity, the Committee shall have the right, in its sole discretion, to cause the immediate
2
Form 3
3/21
forfeiture of all of the Restricted Stock Units (including any dividends credited thereupon) (whether or not vested) shall be immediately forfeited in their
entirety, in which case the Participant shall have no further rights or interests with respect to such Restricted Stock Units (including any such dividends). In the
event that the Participant engages in a Competitive Activity on or after the Payment Date but on or prior to the first anniversary of such Payment Date, the
Company shall have the right to recoup from the Participant, and the Participant shall repay to the Company, within thirty (30) days following demand by the
Company, a payment equal to the Fair Market Value of the aggregate shares of Common Stock payable in respect of such Restricted Stock Units (including
any dividends credited thereupon) on the Payment Date (including any dividends or other distributions thereafter paid thereon); provided, that, the Company
may require the Participant to satisfy such payment obligations hereunder either by forfeiting and returning to the Company such shares of Common Stock,
Restricted Stock Units, dividends or any other Shares, or making a cash payment or any combination of these methods, as determined by the Company in its
sole discretion. The Company and its Subsidiaries, in their sole discretion, shall have the right to set off (or cause to be set off) any amounts otherwise due to
the Participant from the Company (or the applicable Subsidiary) in satisfaction of such repayment obligation, provided that any such amounts are exempt from,
or set off in a manner intended to comply with, the requirements of any applicable law (including, without limitation, Section 409A of the Code).
(c)
The Participant hereby acknowledges and agrees that the forfeiture and recoupment conditions set forth in this Section 3, in
view of the nature of the business in which the Company and its affiliates are engaged, are reasonable in scope and necessary in order to protect the legitimate
business interests of the Company and its affiliates, and that any violation thereof would result in irreparable harm to the Company and its affiliates. The
Participant also acknowledges and agrees that (i) it is a material inducement and condition to the Company’s issuance of the Restricted Stock Units (including
any dividends credited thereupon) that such Participant agrees to be bound by such forfeiture and recoupment conditions and, further, that the amounts required
to be forfeited or repaid to the Company pursuant to forfeiture and recoupment conditions set forth above are reasonable, and (ii) nothing in this Agreement or
the Plan is intended to preclude the Company (or any affiliate thereof) from seeking any remedies available at law, in equity, under contract to the Company or
otherwise, and the Company (or any affiliate thereof) shall have the right to seek any such remedy with respect to the Restricted Stock Units, any dividends
credited thereupon, or otherwise.
(d)
For purposes of this Agreement, the Participant will be deemed to engage in a “Competitive Activity” if, either directly or
indirectly, without the express prior written consent of the Company, the Participant (i) takes other employment with, renders services to, or otherwise engages
in any business activities with, companies or other entities that are competitors of the Company or any of its affiliates, (ii) solicits or induces, or in any manner
attempts to solicit or induce, any person employed by or otherwise providing services to the Company or any of its affiliates, to terminate such person’s
employment or service relationship, as the case may be, with the Company or any of its affiliates, (iii) diverts, or attempts to divert, any person or entity from
doing business with the Company or any of its affiliates or induces, or attempts to induce, any such person or entity from ceasing to be a customer or other
business partner of the Company or any of its affiliates, (iv) violates any agreement between the Participant and the Company or any of its affiliates relating to
the non-disclosure of proprietary or confidential information of the Company or any of its affiliates, and/or (v) conducts himself or herself in a manner
adversely affecting the Company or any of its affiliates, including, without limitation, making false, misleading or negative statements, either orally or in
writing, about the Company or any of its affiliates. The determination as to whether the Participant has engaged in a Competitive Activity shall be made by the
Committee in its sole discretion.
(e)
This Section 3(e) applies solely with respect to Participants who are members of the Company’s Executive Management
Committee. Notwithstanding anything herein to the contrary, Participant agrees and acknowledges that the Restricted Stock Units awarded under this
Agreement and the underlying shares shall be subject to the terms and conditions of the Company’s Incentive Compensation Recoupment Policy approved by
the Board. Notwithstanding the foregoing, Participant agrees that incentive compensation, as defined under of the Dodd-Frank Wall Street Reform and
Consumer Protection Act of 2010 and such regulations as are promulgated thereunder from time to time (“Dodd-Frank”), payable to Participant under this
Agreement shall be subject to any clawback policy adopted or implemented by the Company in respect of Dodd-Frank, or in respect of any other applicable
law or regulation.
4.
Dividend Equivalents.
each Restricted Stock Unit granted to a Participant, provided that such cash dividends shall not be deemed to be reinvested in Shares and will be held
uninvested and without interest and paid in cash if and when the Restricted Stock Unit vests. Stock dividends on Shares shall be credited to a dividend book
entry account on behalf of the Participant with respect to each Restricted Stock Unit granted to a Participant, provided that the Participant shall not be entitled
to such dividend unless and until the Restricted Stock Unit vests.
5.
Rights as a Stockholder
. The Participant shall have no rights as a stockholder with respect to any shares covered by any Restricted Stock Unit
unless and until the Participant has become the holder of record of the shares, and no adjustments shall be made for dividends in cash or other property,
distributions or other rights in respect of any such shares, except as otherwise specifically provided for in this Agreement or the Plan.
6.
Withholding
. Participant shall pay, or make arrangements to pay, in a manner satisfactory to the Company, an amount equal to the amount of all
applicable foreign, federal, state, provincial and local taxes that the Company is required to withhold at any time. In the absence of such arrangements, the
Company or one of its Subsidiaries shall have the right to withhold such taxes from the Participant’s normal pay or other amounts payable to the Participant.
In addition, any statutorily required withholding obligation may be satisfied, in whole or in part, at the Participant’s election, in the form and manner
prescribed by the Committee, by delivery of shares of Common Stock (including shares issuable under this Agreement).
7.
Provisions of Plan Control
. This Agreement is subject to all the terms, conditions and provisions of the Plan, including, without limitation, the
amendment provisions thereof, and to such rules, regulations and interpretations relating to the Plan as may be adopted by the Committee and as may be in
effect from time to time. The Plan is incorporated herein by reference. Capitalized terms in this Agreement that are not otherwise defined shall have the same
meaning as set forth in the Plan. Subject to Section 3, if and to the extent that this Agreement conflicts or is inconsistent with the terms, conditions and
provisions of the Plan, the Plan shall control, and this Agreement shall be deemed to be modified accordingly. This Agreement contains the entire
understanding of the parties with respect to the subject matter hereof and supersedes any prior agreements between the Company and the Participant with
respect to the subject matter hereof.
8.
Amendment.
the provisions of this Agreement to comply with any applicable laws and stock exchange rules and regulations (including, without limitation, Section 409A of
the Code and the regulations thereunder) and may also amend, suspend or terminate this Agreement subject to the terms of the Plan. Except as otherwise
provided in the Plan, no modification or waiver of any of the provisions of this Agreement shall be effective unless in writing and signed by the party against
whom it is sought to be enforced.
9.
Notices.
or by regular United States mail or similar foreign mail or post, first class and prepaid, to the appropriate party at the address set forth below (or such other
address as the party shall from time to time specify):
If to the Company, to:
3
Form 3
3/21
Henry Schein, Inc.
135 Duryea Road
Melville, New York 11747
Attention: General Counsel
If to the Participant, to the address on file with the Company.
10.
No Obligation to Continue Employment or Services
. This Agreement is not an agreement of employment, consultancy or directorship. This
Agreement does not guarantee that the Company or its Subsidiaries will employ or retain, or continue to employ or retain, the Participant during the entire, or
any portion of the, term of this Agreement, including but not limited to any period during which any Restricted Stock Unit is outstanding, nor does it modify in
any respect the Company or its Subsidiaries’ right to terminate or modify the Participant’s employment, service relationship or compensation.
11.
Legend
. The Company may at any time place legends referencing any applicable federal, state or foreign securities law restrictions on all
certificates representing Shares issued pursuant to this Agreement. The Participant shall, at the request of the Company, promptly present to the Company any
and all certificates representing Shares acquired pursuant to this Agreement in the possession of the Participant in order to carry out the provisions of this
Section.
12.
Securities Representations
. The grant of the Restricted Stock Units and issuance of Shares upon vesting of the Restricted Stock Units shall be
subject to, and in compliance with, all applicable requirements of federal, state or foreign securities law. No Shares may be issued hereunder if the issuance of
such Shares would constitute a violation of any applicable federal, state or foreign securities laws or other law or regulations or the requirements of any stock
exchange or market system upon which the Shares may then be listed. As a condition to the settlement of the Restricted Stock Units, the Company may
require the Participant to satisfy any qualifications that may be necessary or appropriate, to evidence compliance with any applicable law or regulation.
The Shares are being issued to the Participant and this Agreement is being made by the Company in reliance upon the following express
representations and warranties of the Participant. The Participant acknowledges, represents and warrants that:
(a)
He or she has been advised that he or she may be an “affiliate” within the meaning of Rule 144 under the Securities Act of
1933, as amended (the “Act”) and in this connection the Company is relying in part on his or her representations set forth in this section.
(b)
If he or she is deemed an affiliate within the meaning of Rule 144 of the Act, the Shares must be held indefinitely unless an
exemption from any applicable resale restrictions is available or the Company files an additional registration statement (or a “re-offer prospectus”) with regard
to such Shares and the Company is under no obligation to register the Shares (or to file a “re-offer prospectus”).
(c)
If he or she is deemed an affiliate within the meaning of Rule 144 of the Act, he or she understands that the exemption from
registration under Rule 144 will not be available unless (i) a public trading market then exists for the Common Stock of the Company, (ii) adequate information
concerning the Company is then available to the public, and (iii) other terms and conditions of Rule 144 or any exemption therefrom are complied with; and
that any sale of the Shares may be made only in limited amounts in accordance with such terms and conditions.
13.
Transfer of Personal Data.
(or any Subsidiary) of any personal data information related to Restricted Stock Units awarded under this Agreement, for legitimate business purposes
(including, without limitation, the administration of the Plan) out of the Participant’s home country and including to countries with less data protection laws
than the data protection laws provided by the Participant’s home country. This authorization/consent is freely given by the Participant.
14.
Delivery Delay.
required for it to comply with any applicable foreign, federal, state or provincial securities law, or any national securities exchange listing requirements and the
Company is not obligated to issue or deliver any securities if, in the opinion of counsel for the Company, the issuance of such Shares shall constitute a
violation by the Participant or the Company of any provisions of any applicable foreign, federal, state or provincial law or of any regulations of any
governmental authority or any national securities exchange. The Participant acknowledges and understands that the Company intends to meet its delivery
obligations in Common Stock with respect to Restricted Stock Units, except as may be prohibited by law or described in this Agreement, the Plan or
supplementary materials.
15.
Miscellaneous.
This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective heirs, legal representatives, successors and
assigns.
(a)
This Agreement shall be governed and construed in accordance with the laws of New York (regardless of the law that might
otherwise govern under applicable New York principles of conflict of laws).
(b)
This Agreement may be executed in one or more counterparts, all of which taken together shall constitute one contract.
(c)
The failure of any party hereto at any time to require performance by another party of any provision of this Agreement shall
not affect the right of such party to require performance of that provision, and any waiver by any party of any breach of any provision of this Agreement shall
not be construed as a waiver of any continuing or succeeding breach of such provision, a waiver of the provision itself, or a waiver of any right under this
Agreement.
(d)
This Agreement and the Plan do not create a joint venture or partnership between the Company and any Subsidiary.
(e)
Notwithstanding any provisions in this Agreement, this grant of Restricted Stock Units shall be subject to any additional
country-specific terms and conditions set forth in Annex 1 to the Agreement for the Participant’s country to the extent applicable. Moreover, if Participant
relocates to one of the countries included in Annex 1, the additional country-specific terms and conditions for such country, if any, will apply to Participant to
the extent that the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.
16.
ACQUIRED RIGHTS
. THE PARTICIPANT ACKNOWLEDGES AND AGREES THAT: (A) THE COMPANY MAY TERMINATE OR
AMEND THE PLAN AT ANY TIME; (B) THE AWARD OF RESTRICTED STOCK UNITS MADE UNDER THIS AGREEMENT IS COMPLETELY
INDEPENDENT OF ANY OTHER AWARD OR GRANT AND IS MADE AT THE SOLE DISCRETION OF THE COMPANY; AND (C) NO PAST
GRANTS OR AWARDS (INCLUDING, WITHOUT LIMITATION, THE RESTRICTED STOCK UNITS AWARDED HEREUNDER) GIVE THE
PARTICIPANT ANY RIGHT TO ANY GRANTS OR AWARDS IN THE FUTURE WHATSOEVER.
4
Form 3
3/21
IN WITNESS WHEREOF
, the parties hereto have executed this Agreement as of the day and year first set forth above.
HENRY SCHEIN, INC.
___________________________
Michael S. Ettinger
Senior Vice President, Corporate & Legal Affairs and Chief of Staff
PARTICIPANT
[Electronic Signature]
[Participant Name]
[Acceptance Date]
ANNEX 1
Additional Country Specific Terms and Conditions
for the Restricted Stock Unit Agreement
This Annex 1 includes additional terms and conditions that govern the Restricted Stock Units granted to the Participant under the Plan if the
Participant works or resides in, or is otherwise subject to the taxes imposed by, one of the countries listed below. This Annex 1 also includes other information
that may impact the Participant’s participation in the Plan. Certain capitalized terms used but not defined in this Annex 1 have the meanings set forth in the
Plan and/or the Agreement. This Annex 1 forms part of the Agreement and should be read in conjunction with the Agreement and the Plan.
The Participant agrees to sign any additional agreements or undertakings that may be necessary or advisable in order to comply with applicable law
or facilitate the administration of the Plan. Furthermore, the Participant acknowledges that the applicable law of the country in which the Participant is subject
to taxes or is residing or working at the time of grant or vesting of the Restricted Stock Units or the sale of shares of Common Stock received pursuant to the
Restricted Stock Units (including any rules or regulations governing securities, foreign exchange, tax, labor, employment, or other matters) may restrict or
prevent the issuance of shares of Common Stock or subject the Participant to additional terms and conditions or procedural or regulatory requirements that the
Participant is or will be solely responsible for and must fulfill. Such requirements may be outlined in but are not limited to items listed below in this Annex 1.
If the Participant is a citizen or resident of a country other than the country in which he or she is subject to taxes or is residing and/or working, or if
the Participant transfers employment or residency after the Restricted Stock Units are granted to him or her, the information contained in this Annex 1 may not
be applicable to the Participant. Tax laws are often complex and outcomes can vary depending on individual circumstances. Accordingly, the Participant is
advised to seek appropriate professional advice as to how tax and other relevant laws in the applicable country may apply to his or her situation.
UNITED STATES
The second to last sentence of Section 2(d) of Agreement is hereby deleted in its entirety and replaced with the following:
“For the purposes of this Agreement, a “Change of Control” shall mean the occurrence of a Section 409A Change of Control (as defined in Section
17).”
As of the Grant Date, if the Participant either (i) qualifies for Retirement (as defined in Section 2(c) of the Agreement) or (ii) may become eligible to qualify
for Retirement prior to the Scheduled Payment Date, Section 4 of the Agreement is hereby deleted in its entirety and replaced with the following:
“Dividend Equivalents. Cash dividends on Shares shall be credited to a dividend book entry account on behalf of the Participant with respect to
each Restricted Stock Unit granted to the Participant, provided that such cash dividends shall not be deemed to be reinvested in Shares and will be held
uninvested and without interest. The Participant’s right to receive any such cash dividends shall vest if and when the related Restricted Stock Unit vests, and
such cash dividends shall be paid in cash to the Participant if and when the related Restricted Stock Unit is paid to the Participant. Stock dividends on Shares
shall be credited to a dividend book entry account on behalf of the Participant with respect to each Restricted Stock Unit granted to the Participant. The
Participant’s right to receive any such stock dividends shall vest if and when the related Restricted Stock Unit vests, and such stock dividends shall be paid in
stock to the Participant if and when the related Restricted Stock Unit is paid to the Participant.”
The following shall be added to the Agreement as a new Section 17:
“Change of Control Defined.
For purposes of this Agreement, a “Section 409A Change of Control” shall be deemed to have occurred upon:
(i) an acquisition by any Person of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Act) of (A) 50% or more of the
then outstanding Shares or (B) 33% or more of the total combined voting power of the then outstanding voting securities of HSI entitled to vote
generally in the election of directors (the “Outstanding HSI Voting Securities”); excluding, however, the following: (w) any acquisition directly
from the Company, other than an acquisition by virtue of the exercise of a conversion privilege unless the security being so converted was itself
acquired directly from the Company, (x) any acquisition by the Company, (y) any acquisition by an employee benefit plan (or related trust)
sponsored or maintained by the Company or (z) any acquisition by any corporation pursuant to a reorganization, merger, consolidation or similar
corporate transaction (in each case, a “Corporate Transaction”), if, pursuant to such Corporate Transaction, the conditions described in clauses (A),
(B) and (C) of paragraph (iii) below are satisfied; or
(ii) within any 12-month period beginning on or after the date of the Agreement, the individuals who constitute the Board immediately before the
beginning of such period (the Board as of the date hereof shall be hereinafter referred to as the “Incumbent Board”) cease for any reason to
5
Form 3
3/21
constitute at least a majority of the Board; provided that for purposes of this Subsection any individual who becomes a member of the Board
subsequent to the date hereof whose election, or nomination for election by HSI’s stockholders, was approved by a vote of at least a majority of
those individuals who are members of the Board and who are also members of the Incumbent Board (or deemed to be such pursuant to this proviso)
shall be considered as though such individual were a member of the Incumbent Board; but, provided further, that any such individual whose initial
assumption of office occurs as a result of either an actual or threatened election contest (as such terms are used in Rule 14a-11 of Regulation 14A
promulgated under the Act) or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board shall
not be so considered as a member of the Incumbent Board; or
(iii) the consummation of a Corporate Transaction or, if consummation of such Corporate Transaction is subject to the consent of any government
or governmental agency, the obtaining of such consent (either explicitly or implicitly by consummation); excluding, however, such a Corporate
Transaction pursuant to which (A) all or substantially all of the individuals and entities who are the beneficial owners, respectively, of the
outstanding Shares and Outstanding HSI Voting Securities immediately prior to such Corporate Transaction will beneficially own, directly or
indirectly, more than 60% of, respectively, the outstanding shares of common stock of the corporation resulting from such Corporate Transaction
and the combined voting power of the outstanding voting securities of such corporation entitled to vote generally in the election of directors, in
substantially the same proportions as their ownership, immediately prior to such Corporate Transaction, of the outstanding Shares and Outstanding
HSI Voting Securities, as the case may be, (B) no Person (other than the Company, any employee benefit plan (or related trust) of the Company or
the corporation resulting from such Corporate Transaction and any Person beneficially owning, immediately prior to such Corporate Transaction,
directly or indirectly, 33% or more of the outstanding Shares or Outstanding HSI Voting Securities, as the case may be, will beneficially own,
directly or indirectly, 33% or more of, respectively, the outstanding shares of common stock of the corporation resulting from such Corporate
Transaction or the combined voting power of the then outstanding securities of such corporation entitled to vote generally in the election of
directors and (C) individuals who were members of the Incumbent Board will constitute at least a majority of the members of the board of directors
of the corporation resulting from such Corporate Transaction; or
(iv) the sale or other disposition of all or substantially all of the assets of the Company; excluding, however, such sale or other disposition to a
corporation with respect to which, following such sale or other disposition, (x) more than 60% of, respectively, the then outstanding shares of
common stock of such corporation and the combined voting power of the then outstanding voting securities of such corporation entitled to vote
generally in the election of directors will be then beneficially owned, directly or indirectly, by all or substantially all of the individuals and entities
who were the beneficial owners, respectively, of the outstanding Common Stock and Outstanding HSI Voting Securities immediately prior to such
sale or other disposition in substantially the same proportion as their ownership, immediately prior to such sale or other disposition, of the
outstanding Common Stock and Outstanding HSI Voting Securities, as the case may be, (y) no Person (other than the Company and any employee
benefit plan (or related trust) of the Company or such corporation and any Person beneficially owning, immediately prior to such sale or other
disposition, directly or indirectly, 33% or more of the outstanding Common Stock or Outstanding HSI Voting Securities, as the case may be) will
beneficially own, directly or indirectly, 33% or more of, respectively, the then outstanding shares of common stock of such corporation and the
combined voting power of the then outstanding voting securities of such corporation entitled to vote generally in the election of directors and (z)
individuals who were members of the Incumbent Board will constitute at least a majority of the members of the board of directors of such
corporation.
(v) No event set forth herein shall constitute a “Section 409A Change of Control” unless such event also qualifies as a “change in control event” for
purposes of Treasury Regulation § 1.409A-3(i)(5). Accordingly, the definition of “Section 409A Change of Control” set forth herein shall be
limited, construed and interpreted in accordance with Section 409A and the regulations issued thereunder.”
The following shall be added to the Agreement as a new Section 18:
This Agreement is subject to Section 16(i) of the Plan, and any provisions in this Agreement providing for the payment of
“nonqualified deferred compensation” (as defined in Section 409A of the Code and the Treasury regulations thereunder) to the Participant are intended to
comply with, or be exempt from, the requirements of Section 409A of the Code, and this Agreement shall be interpreted in accordance therewith. Neither
party individually or in combination may accelerate or defer the timing of the payment of any such nonqualified deferred compensation, except in compliance
with Section 409A of the Code and this Agreement, and no amount shall be paid prior to the earliest date on which it is permitted to be paid under Section
409A of the Code and this Agreement. In no event whatsoever shall the Company be liable for any additional tax, interest or penalty that may be imposed on
the Participant as a result of Section 409A of the Code or any damages for failing to comply with Section 409A of the Code. A Termination of Employment or
Retirement shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits subject
to Section 409A of the Code upon or following a Termination of Employment or Retirement, as applicable, unless such Termination of Employment or
Retirement, as applicable, is also a “separation from service” within the meaning of Section 409A of the Code and, for purposes of any such provision of this
Agreement, references to a “termination,” “termination of employment” or like terms shall mean “separation from service.” If the Participant is a “specified
employee,” upon his or her “separation from service” (as defined under Section 409A of the Code under such definitions and procedures as established by the
Company in accordance with Section 409A of the Code), any portion of a payment, settlement, or other distribution made upon such a “separation from
service” that would cause the acceleration of, or an addition to, any taxes pursuant to Section 409A of the Code will not commence or be paid until a date that
is six (6) months and one (1) day following the applicable “separation from service.” Any payments, settlements, or other distributions that are delayed
pursuant to this Section 18 following the applicable “separation from service” shall be accumulated and paid to the Participant in a lump sum without interest
on the first business day immediately following the required delay period. Any amounts payable hereunder that satisfy the short-term deferral exception in
Treas. Reg. §1.409A-1(b)(4) shall not be subject to Section 409A of the Code. Whenever a payment under this Agreement may be paid within a specified
period, the actual date of payment within the specified period shall be within the Company’s sole discretion.”
EXHIBIT 31.1
CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES
I, Stanley M. Bergman, certify that:
1.
I have reviewed this quarterly report on Form 10-Q of Henry Schein, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and
have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures
to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end
of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant's internal control over financial reporting that
occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the
case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal
control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of
directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant's ability to record,
process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a
significant role in the registrant's internal control over financial reporting.
Date: May 4, 2021
/s/ Stanley M. Bergman
Stanley M. Bergman
Chairman and Chief Executive Officer
EXHIBIT 31.2
CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES
I, Steven Paladino, certify that:
1.
I have reviewed this quarterly report on Form 10-Q of Henry Schein, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and
have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures
to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end
of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant's internal control over financial reporting that
occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the
case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal
control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of
directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant's ability to record,
process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a
significant role in the registrant's internal control over financial reporting.
Date: May 4, 2021
/s/ Steven Paladino
Steven Paladino
Executive Vice President and
Chief Financial Officer
EXHIBIT 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002
In connection with the quarterly report on Form 10-Q of Henry Schein, Inc. (the “Company”) for the period
ending March 27, 2021, as filed with the Securities and Exchange Commission on the date hereof (the
“Report”), I, Stanley M. Bergman, the Chairman and Chief Executive Officer of the Company, and I, Steven
Paladino, Executive Vice President and Chief Financial Officer of the Company, do hereby certify pursuant
to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best
of my knowledge and belief that:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act
of 1934, as amended; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company.
/s/ Stanley M. Bergman
Dated: May 4, 2021
Stanley M. Bergman
Chairman and Chief Executive Officer
Dated: May 4, 2021
/s/ Steven Paladino
Steven Paladino
Executive Vice President and
Chief Financial Officer
This certification accompanies each Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and
shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has
been provided to the Company and will be retained by the Company and furnished to the Securities and
Exchange Commission or its staff upon request.